UNITED STATES	OMB APPROVAL
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549	OMB Number:  3235-0582
	Expires:  May 31, 2021
	Estimated average burden hours per response........7.2

FORM N-PX

ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED
MANAGEMENT INVESTMENT COMPANY

Investment Company Act file number  811- 06565

Tekla Life Sciences Investors

(Exact name of registrant as specified in charter)

100 Federal Street, 19th Floor, Boston, MA	02110
(Address of principal executive offices)	(Zip code)

Laura Woodward
Tekla Life Sciences Investors
100 Federal Street, 19^th Floor, Boston MA 02110

(Name and address of agent for service)

Registrant’s telephone number, including area code:  617-772-8500

Date of fiscal year end:  September 30

Date of reporting period:  7/1/19-6/30/20

Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (ss.ss. 239.24 and 274.5 of this chapter), to file reports with the Commission, no later than August 31 of each year, containing the registrant’s proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b1-4). The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.

A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget (“OMB”) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. ss. 3507.

Item 1. Proxy Voting Record.

HQL Vote Summary

AC IMMUNE SA

Security	H00263105	Meeting Type	Annual
Ticker Symbol	ACIU	Meeting Date	26-Jun-2020
Record Date	18-May-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1	Approval of the Annual Report, Annual Statutory Financial Statements and Financial Statements under IFRS for the Year 2019	Management	For	For
2	Appropriation of Profit	Management	For	For
3	Discharge of the Members of the Board of Directors and of the Executive Committee	Management	For	For
4A	Binding vote on Total Non-Performance-Related Compensation for Members of the Board of Directors from 1 July 2020 to 30 June 2021	Management	For	For
4B	Binding vote on Equity for Members of the Board of Directors from 1 July 2020 to 30 June 2021	Management	For	For
4C	Binding vote on Total Non-Performance-Related Compensation for Members of the Executive Committee from 1 July 2020 to 30 June 2021	Management	For	For
4D	Binding vote on Total Variable Compensation for Members of the Executive Committee for the current year 2020	Management	For	For
4E	Binding vote on Equity for Members of the Executive Committee from 1 July 2020 to 30 June 2021	Management	For	For
4F	Advisory vote on the 2019 Compensation Report	Management	For	For
5AA	Re-election to the Board of Director: Douglas Williams as member and Chairman	Management	For	For
5AB	Re-election to the Board of Director: Martin Velasco as member and Vice-Chairman	Management	For	For
5AC	Re-election to the Board of Director: Peter Bollmann	Management	For	For
5AD	Re-election to the Board of Director: Andrea Pfeifer	Management	For	For
5AE	Re-election to the Board of Director: Tom Graney	Management	For	For
5AF	Re-election to the Board of Director: Werner Lanthaler	Management	For	For
5AG	Re-election to the Board of Director: Roy Twyman	Management	For	For
5BA	Re-election of the Member of the Compensation, Nomination & Corporate Governance Committee: Douglas Williams	Management	For	For
5BB	Re-election of the Member of the Compensation, Nomination & Corporate Governance Committee: Martin Velasco	Management	For	For
5BC	Re-election of the Member of the Compensation, Nomination & Corporate Governance Committee: Tom Graney	Management	For	For
5C	Re-election of PricewaterhouseCoopers SA (Pully) as statutory auditors	Management	For	For
5D	Re-election of Reymond & Associés (Lausanne) as independent proxy	Management	For	For
6A	Amendments to the Articles of Association: Authorized Share Capital	Management	For	For
6B	Amendments to the Articles of Association: Conditional Capital Increase for Bonds and Similar Debt Instruments	Management	For	For
A.	If a new agenda item or a new proposal for an existing agenda item is put before the meeting, I/we hereby authorize and instruct the independent proxy to vote as follows:	Management	For

ACADIA PHARMACEUTICALS INC.

Security	004225108	Meeting Type	Annual
Ticker Symbol	ACAD	Meeting Date	23-Jun-2020
Record Date	24-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	James M. Daly		For	For
	2	Edmund P. Harrigan, M.D		For	For
2.	To approve an amendment to our 2004 Employee Stock Purchase Plan to increase the aggregate number of shares of common stock authorized for issuance thereunder by 3,000,000 shares.		Management	For	For
3.	To approve our non-employee director compensation policy.		Management	For	For
4.	To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement for the annual meeting.		Management	For	For
5.	To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For

ACCELERON PHARMA INC.

Security	00434H108	Meeting Type	Annual
Ticker Symbol	XLRN	Meeting Date	04-Jun-2020
Record Date	07-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class I Director: Thomas A. McCourt	Management	For	For
1B.	Election of Class I Director: Francois Nader, M.D.	Management	For	For
2.	To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the proxy statement.	Management	For	For
3.	To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.	Management	For	For

AERIE PHARMACEUTICALS, INC.

Security	00771V108	Meeting Type	Annual
Ticker Symbol	AERI	Meeting Date	11-Jun-2020
Record Date	14-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	V. Anido, Jr., Ph.D.		For	For
	2	B. McGraw, III, Pharm.D		For	For
	3	J. McHugh		For	For
2.	Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For
3.	To approve, by a non-binding vote, the compensation of our named executive officers ("say-on-pay").		Management	For	For

AERPIO PHARMACEUTICALS, INC.

Security	00810B105	Meeting Type	Annual
Ticker Symbol	ARPO	Meeting Date	24-Jun-2020
Record Date	27-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Joseph Gardner		For	For
	2	Steven Prelack		For	For
2.	To approve a potential amendment to our Amended and Restated Certificate of Incorporation to effect a Reverse Stock Split of the Common Stock at a ratio within the range of 1-for-15 to 1-for-25, such ratio to be determined in the sole discretion of the Board of Directors.		Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as Aerpio's independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For

AGIOS PHARMACEUTICALS, INC.

Security	00847X104	Meeting Type	Annual
Ticker Symbol	AGIO	Meeting Date	28-May-2020
Record Date	07-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Paul J. Clancy		For	For
	2	Ian T. Clark		For	For
2.	To vote, on an advisory basis, to approve named executive officer compensation.		Management	For	For
3.	To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For

ALEXION PHARMACEUTICALS, INC.

Security	015351109	Meeting Type	Annual
Ticker Symbol	ALXN	Meeting Date	13-May-2020
Record Date	16-Mar-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Felix J. Baker		For	For
	2	David R. Brennan		For	For
	3	Christopher J. Coughlin		For	For
	4	Deborah Dunsire		For	For
	5	Paul A. Friedman		For	For
	6	Ludwig N. Hantson		For	For
	7	John T. Mollen		For	For
	8	Francois Nader		For	For
	9	Judith A. Reinsdorf		For	For
	10	Andreas Rummelt		For	For
2.	Proposal No. 2 - Ratification of appointment by the Board of Directors of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm.		Management	For	For
3.	Proposal No. 3 - Approval of a non-binding advisory vote of the 2019 compensation paid to Alexion's named executive officers.		Management	For	For
4.	Proposal No. 4 - Shareholder proposal requesting certain By-law amendments to lower the threshold for shareholders to call a special meeting.		Shareholder	Against	For

ALKERMES PLC

Security	G01767105	Meeting Type	Annual
Ticker Symbol	ALKS	Meeting Date	20-May-2020
Record Date	17-Mar-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class III Director to serve for a three-year term: Shane M. Cooke	Management	For	For
1.2	Election of Class III Director to serve for a three-year term: Richard B. Gaynor, M.D.	Management	For	For
1.3	Election of Class III Director to serve for a three-year term: Paul J. Mitchell	Management	For	For
1.4	Election of Class III Director to serve for a three-year term: Richard F. Pops	Management	For	For
2.	To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers.	Management	For	For
3.	To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Company's Board of Directors (the Board) to set the independent auditor and accounting firm's remuneration.	Management	For	For
4.	To approve the Alkermes plc 2018 Stock Option and Incentive Plan, as amended.	Management	For	For

ALLAKOS INC.

Security	01671P100	Meeting Type	Annual
Ticker Symbol	ALLK	Meeting Date	26-May-2020
Record Date	09-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	John McKearn, Ph.D.		For	For
	2	Paul Walker		For	For
2.	Ratification and approval of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For
3.	Approval, on an advisory non-binding basis, the frequency of future advisory votes to approve the compensation of our named executive officers.		Management	1 Year	Against

ALLOGENE THERAPEUTICS, INC.

Security	019770106	Meeting Type	Annual
Ticker Symbol	ALLO	Meeting Date	05-Jun-2020
Record Date	21-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Deborah Messemer	Management	For	For
1B.	Election of Director: Todd Sisitsky	Management	For	For
1C.	Election of Director: Owen Witte, M.D.	Management	For	For
2.	To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.	Management	1 Year	For
3.	To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020.	Management	For	For

ALNYLAM PHARMACEUTICALS, INC.

Security	02043Q107	Meeting Type	Annual
Ticker Symbol	ALNY	Meeting Date	06-May-2020
Record Date	09-Mar-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class I Director: Michael W. Bonney	Management	For	For
1B.	Election of Class I Director: John M. Maraganore, Ph.D.	Management	For	For
1C.	Election of Class I Director: Phillip A. Sharp, Ph.D.	Management	For	For
2.	To approve an Amendment to our 2018 Stock Incentive Plan, as amended.	Management	For	For
3.	To approve an Amendment to our Amended and Restated 2004 Employee Stock Purchase Plan, as amended.	Management	For	For
4.	To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.	Management	For	For
5.	To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2020.	Management	For	For

AMARIN CORPORATION PLC

Security	023111206	Meeting Type	Annual
Ticker Symbol	AMRN	Meeting Date	13-Jul-2020
Record Date	22-May-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To re-elect Dr. Lars G. Ekman as a director.	Management	For	For
2.	To re-elect Mr. Joseph S. Zakrzewski as a director.	Management	For	For
3.	To hold an advisory (non-binding) vote to approve the compensation of the Company's "named executive officers" as described in full in the "Executive Compensation Discussion and Analysis" section, the tabular disclosure regarding such compensation, and the accompanying narrative disclosure in the accompanying Proxy Statement.	Management	For	For
4.	To appoint Ernst & Young LLP as auditors of the Company to hold office until the conclusion of the next general meeting at which accounts are laid before the Company and to authorize the Audit Committee of the Board of Directors of the Company to fix the auditors' remuneration as described in full in the accompanying Proxy Statement.	Management	For	For
5.	To approve the Amarin Corporation plc 2020 Stock Incentive Plan as described in full in the accompanying Proxy Statement in advance of the expiration of the 2011 Plan.	Management	For	For

AMGEN INC.

Security	031162100	Meeting Type	Annual
Ticker Symbol	AMGN	Meeting Date	19-May-2020
Record Date	20-Mar-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Dr. Wanda M. Austin	Management	For	For
1B.	Election of Director: Mr. Robert A. Bradway	Management	For	For
1C.	Election of Director: Dr. Brian J. Druker	Management	For	For
1D.	Election of Director: Mr. Robert A. Eckert	Management	For	For
1E.	Election of Director: Mr. Greg C. Garland	Management	For	For
1F.	Election of Director: Mr. Fred Hassan	Management	For	For
1G.	Election of Director: Mr. Charles M. Holley, Jr.	Management	For	For
1H.	Election of Director: Dr. Tyler Jacks	Management	For	For
1I.	Election of Director: Ms. Ellen J. Kullman	Management	For	For
1J.	Election of Director: Dr. Ronald D. Sugar	Management	For	For
1K.	Election of Director: Dr. R. Sanders Williams	Management	For	For
2.	Advisory vote to approve our executive compensation.	Management	For	For
3.	To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2020.	Management	For	For
4.	Stockholder proposal to require an independent board chair.	Shareholder	For	Against

AMICUS THERAPEUTICS, INC.

Security	03152W109	Meeting Type	Annual
Ticker Symbol	FOLD	Meeting Date	04-Jun-2020
Record Date	13-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Lynn D. Bleil		For	For
	2	Bradley L. Campbell		For	For
	3	Robert Essner		For	For
	4	Ted W. Love, M.D.		For	For
2.	Approval of the Amended and Restated 2007 Equity Incentive Plan to add 9,500,000 shares to the equity pool.		Management	For	For
3.	Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For
4.	Approval, on an advisory basis, the Company's executive compensation.		Management	For	For

AMPHIVENA THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	27-Aug-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of Certificate of Amendment to Amended and Restated Certificate of Incorporation	Management	For	For
2.	Increase in Authorized Shares Reserved for Issuance under the Company's 2013 Stock Incentive Plan	Management	For	For
3.	Omnibus Resolutions	Management	For	For

AMPHIVENA THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	4-Nov-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Election of Director	Management	For	For
2.	Increase in Authorized Shares Reserved for Issuance under the Company's 2013 Stock Incentive Plan	Management	For	For
3.	Omnibus Resolutions	Management	For	For

ANAPTYSBIO INC

Security	032724106	Meeting Type	Annual
Ticker Symbol	ANAB	Meeting Date	19-Jun-2020
Record Date	20-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Hollings Renton		For	For
	2	John P. Schmid		For	For
2.	To ratify the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For
3.	Non-binding advisory vote on compensation of our named executive officers.		Management	For	For

APELLIS PHARMACEUTICALS INC.

Security	03753U106	Meeting Type	Annual
Ticker Symbol	APLS	Meeting Date	01-Jun-2020
Record Date	13-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Gerald Chan		For	For
	2	Cedric Francois		For	For
2.	To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For
3.	To approve an advisory vote on executive compensation.		Management	For	For

ARCA BIOPHARMA, INC.

Security	00211Y506	Meeting Type	Annual
Ticker Symbol	ABIO	Meeting Date	10-Dec-2019
Record Date	14-Oct-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Dr. Linda Grais		Withheld	Against
	2	Dr. Anders Hove		Withheld	Against
2.	To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as independent registered public accounting firm of the Company for its fiscal year ending December 31, 2019.		Management	For	For
3.	To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.		Management	For	For
4.	To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.		Management	1 Year	For

ARDELYX, INC

Security	039697107	Meeting Type	Annual
Ticker Symbol	ARDX	Meeting Date	09-Jun-2020
Record Date	15-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Robert Bazemore		For	For
	2	Gordon Ringold, Ph.D.		For	For
	3	Richard Rodgers		For	For
2.	To ratify the selection, by the Audit Committee of our Board of Directors, of Ernst & Young, LLP as the independent registered public accounting firm of the Company for the fiscal year ended December 31, 2020.		Management	For	For
3.	To approve, on a non-binding, advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").		Management	For	For
4.	To approve, on a non-binding, advisory basis, whether a Say-on-Pay vote should occur every one (1) year, every two (2) years or every three (3) years.		Management	1 Year	For

ARENA PHARMACEUTICALS, INC.

Security	040047607	Meeting Type	Annual
Ticker Symbol	ARNA	Meeting Date	12-Jun-2020
Record Date	20-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Jayson Dallas, M.D.		For	For
	2	Oliver Fetzer, Ph.D.		For	For
	3	Kieran T. Gallahue		For	For
	4	Jennifer Jarrett		For	For
	5	Amit D. Munshi		For	For
	6	Garry A. Neil, M.D.		For	For
	7	Tina S. Nova, Ph.D.		For	For
	8	Manmeet S. Soni		For	For
2.	To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice.		Management	For	For
3.	To approve an amendment to our Amended and Restated Certificate of Incorporation to effect an increase in the total number of authorized shares of our common stock.		Management	For	For
4.	To approve the Arena Pharmaceuticals, Inc. 2020 Long- Term Incentive Plan.		Management	For	For
5.	To ratify the appointment of KPMG LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2020.		Management	For	For

ARGENX SE

Security	04016X101	Meeting Type	Special
Ticker Symbol	ARGX	Meeting Date	25-Nov-2019
Record Date	28-Oct-2019

Item	Proposal	Proposed by	Vote	For/Against Management
2.	Amendment of the articles of association of argenx SE to increase the maximum share capital and granting a proxy to each of the directors of the Company and employees of Freshfields Bruckhaus Deringer LLP in having the deed of amendment executed.	Management	For	For
3.	Approval of the amended argenx option plan.	Management	For	For
4.	Authorization of the board of directors to grant options (rights to subscribe for shares) up to a maximum of 4% of the outstanding capital at the date of the general meeting, pursuant to, and within the limits of, the argenx option plan, for a period of 18 months from the general meeting.	Management	For	For

ARGENX SE

Security	04016X101	Meeting Type	Annual
Ticker Symbol	ARGX	Meeting Date	12-May-2020
Record Date	14-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
3.	Adoption of the new remuneration policy	Management	For	For
4.	Advisory vote to approve the 2019 remuneration report	Management	For	For
5b.	Adoption of the 2019 annual accounts	Management	For	For
5d.	Allocation of losses of the Company in the financial year 2019 to the retained earnings of the Company	Management	For	For
5e.	Proposal to release the members of the board of directors from liability for their respective duties carried out in the financial year 2019	Management	For	For
6.	Re-appointment of Pamela Klein as non-executive director to the board of directors of the Company	Management	For	For
7.	Authorization of the board of directors to grant rights to subscribe for shares in the capital of the Company up to a maximum of 4% of the outstanding capital at the date of the general meeting, pursuant to, and within the limits of, the argenx option plan, for a period of 18 months from the annual general meeting and to limit or exclude statutory pre-emptive rights, if any	Management	For	For
8.	Authorization of the board of directors to issue shares and grant rights to subscribe for shares in the share capital of the Company up to a maximum of 10% of the outstanding capital at the date of the general meeting, for a period of 18 months from the annual general meeting and to limit or exclude statutory pre-emptive rights, if any	Management	For	For
9.	Authorization of the board of directors to issue additional shares in the share capital of the company up to a maximum of 10% of the outstanding share capital at the date of the general meeting (in addition to the authorizations under 7 and 8), for a period starting on the date of this general meeting and ending on 31 December 2020, for the purpose of a possible public offering of such shares and to limit or exclude statutory pre-emptive rights, if any	Management	For	For
10.	Appointment of Deloitte Accountants B.V. as statutory auditor for the 2020 financial year	Management	For	For

ARROWHEAD PHARMACEUTICALS, INC.

Security	04280A100	Meeting Type	Annual
Ticker Symbol	ARWR	Meeting Date	19-Mar-2020
Record Date	22-Jan-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Christopher Anzalone		For	For
	2	Marianne De Backer		For	For
	3	Mauro Ferrari		For	For
	4	Douglass Given		For	For
	5	Michael S. Perry		For	For
	6	William Waddill		For	For
2.	To approve, in an advisory (non-binding) vote, the compensation paid to the Company's named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the compensation tables and narrative discussion.		Management	For	For
3.	To approve an amendment to the Company's Amended and Restated Bylaws to implement a majority vote standard in uncontested elections of directors.		Management	For	For
4.	To ratify the selection of Rose, Snyder & Jacobs LLP as independent auditors of the Company for the fiscal year ending September 30, 2020.		Management	For	For

ASCENDIS PHARMA A S

Security	04351P101	Meeting Type	Annual
Ticker Symbol	ASND	Meeting Date	29-May-2020
Record Date	24-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Election of Chairman of the Meeting	Management	For	For
2.	Report on the Company's Activities during the Past Year	Management	For	For
3.	Presentation of Audited Annual Report with Auditor's Statement for Approval and Discharge of the Board of Directors and Management	Management	For	For
4.	Resolution on Application of Profits or Covering of Losses as per the Adopted Annual Report	Management	For	For
5A.	Election of Board Member Class II, with a term expiring at the annual general meeting to be held in 2022: Albert Cha	Management	For	For
5B.	Election of Board Member Class II, with a term expiring at the annual general meeting to be held in 2022: Birgitte Volck	Management	For	For
5C.	Election of Board Member Class II, with a term expiring at the annual general meeting to be held in 2022: Lars Holtug	Management	For	For
6.	Election of State-authorized Public Auditor	Management	For	For
7.	Any proposals from the Board of Directors and/or Shareholders The Board of Directors proposes to amend the Articles of Association by renewing the authorisation to the Board of Directors to issue up to nominal 2,000,000 new warrants. The exercise price of such warrants shall be determined by the Board of Directors and shall equal at least to the market price of the shares at the time of issuance. Please refer to the Notice for additional information.	Management	For	For

ATRECA INC

Security	04965G109	Meeting Type	Annual
Ticker Symbol	BCEL	Meeting Date	10-Jun-2020
Record Date	17-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	David Lacey, MD		For	For
	2	Lindsey Rolfe, MBChB		For	For
2.	Ratification of the selection of OUM & Co. LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020.		Management	For	For

AURINIA PHARMACEUTICALS INC.

Security	05156V102	Meeting Type	Annual and Special Meeting
Ticker Symbol	AUPH	Meeting Date	02-Jun-2020
Record Date	20-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
01	TO FIX THE NUMBER OF DIRECTORS TO BE ELECTED AT NINE (9).		Management	For	For
02	DIRECTOR		Management
	1	DR. GEORGE MILNE		For	For
	2	MR. PETER GREENLEAF		For	For
	3	DR. DAVID R.W. JAYNE		For	For
	4	MR. JOSEPH P. HAGAN		For	For
	5	DR. MICHAEL HAYDEN		For	For
	6	DR. DANIEL BILLEN		For	For
	7	MR. R.H. MACKAY-DUNN		For	For
	8	MS. JILL LEVERSAGE		For	For
	9	MR. TIMOTHY P. WALBERT		For	For
03	REAPPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS AUDITORS OF THE COMPANY FOR THE ENSUING YEAR.		Management	For	For
04	TO CONSIDER AND, IF DEEMED APPROPRIATE, TO PASS A NON-BINDING ADVISORY "SAY ON PAY" RESOLUTION APPROVING THE COMPANY'S APPROACH TO EXECUTIVE COMPENSATION, THE FULL TEXT OF WHICH IS SET OUT IN THE COMPANY'S CIRCULAR FOR THE MEETING.		Management	For	For
05	TO CONSIDER, AND IF DEEMED APPROPRIATE, APPROVE, WITH OR WITHOUT VARIATION, AN ORDINARY RESOLUTION RATIFYING, CONFIRMING AND APPROVING THE COMPANY'S AMENDED AND RESTATED BY-LAW NO. 2 AS ADOPTED BY THE COMPANY'S BOARD OF DIRECTORS (THE "BOARD") TO ALLOW THE COMPANY TO HOLD FULLY VIRTUAL SHAREHOLDER MEETINGS AND SHAREHOLDER MEETINGS OUTSIDE OF ALBERTA, AMONG OTHER AMENDMENTS, THE FULL TEXT OF WHICH IS SET OUT IN THE COMPANY'S CIRCULAR FOR THE MEETING.		Management	For	For
06	TO CONSIDER, AND IF DEEMED APPROPRIATE, APPROVE, WITH OR WITHOUT VARIATION, A SPECIAL RESOLUTION AMENDING THE ARTICLES OF THE COMPANY TO PERMIT MEETINGS OF SHAREHOLDERS TO BE HELD OUTSIDE OF ALBERTA, THE FULL TEXT OF WHICH IS SET OUT IN THE COMPANY'S CIRCULAR FOR THE MEETING.		Management	For	For
07	TO CONSIDER AND, IF DEEMED APPROPRIATE, APPROVE, WITH OR WITHOUT VARIATION, AN ORDINARY RESOLUTION RATIFYING, CONFIRMING AND APPROVING THE COMPANY'S AMENDMENTS TO THE STOCK OPTION PLAN AS ADOPTED BY THE BOARD TO EXPAND THE TYPES OF EQUITY BASED AWARDS AVAILABLE TO GRANT, THE FULL TEXT OF WHICH IS SET OUT IN THE COMPANY'S CIRCULAR FOR THE MEETING.		Management	For	For
08	TO CONSIDER AND, IF DEEMED APPROPRIATE, APPROVE, WITH OR WITHOUT VARIATION, AN ORDINARY RESOLUTION APPROVING ALL UNALLOCATED ENTITLEMENTS UNDER THE COMPANY'S STOCK OPTION PLAN, THE FULL TEXT OF WHICH IS SET OUT IN THE COMPANY'S CIRCULAR FOR THE MEETING.		Management	For	For

AVADEL PHARMACEUTICALS PLC

Security	05337M104	Meeting Type	Annual
Ticker Symbol	AVDL	Meeting Date	06-Aug-2019
Record Date	30-May-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Gregory J. Divis	Management	For	For
1b.	Election of Director: Dr. Eric J. Ende	Management	For	For
1c.	Election of Director: Geoffrey M. Glass	Management	For	For
1d.	Election of Director: Kevin Kotler	Management	For	For
1e.	Election of Director: Linda S. Palczuk	Management	For	For
1f.	Election of Director: Peter Thornton	Management	For	For
2.	To ratify, in a non-binding vote, the appointment of Deloitte & Touche LLP as the Company's independent registered public auditor and accounting firm for the fiscal year ending December 31, 2019 and to authorize, in a binding vote, the Audit Committee of the Board to set the independent registered public auditor and accounting firm remuneration.	Management	For	For

AVROBIO, INC.

Security	05455M100	Meeting Type	Annual
Ticker Symbol	AVRO	Meeting Date	04-Jun-2020
Record Date	06-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Ian Clark		For	For
	2	Annalisa Jenkins		For	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For
3.	To approve an amendment to the AVROBIO, Inc. 2018 Stock Option and Incentive Plan.		Management	For	For

AXONICS MODULATION TECHNOLOGIES INC

Security	05465P101	Meeting Type	Annual
Ticker Symbol	AXNX	Meeting Date	24-Jun-2020
Record Date	28-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Raymond W. Cohen	Management	For	For
1B.	Election of Director: Erik Amble, Ph.D.	Management	For	For
1C.	Election of Director: Juliet Tammenoms Bakker	Management	For	For
1D.	Election of Director: Robert E. McNamara	Management	For	For
1E.	Election of Director: Michael H. Carrel	Management	For	For
1F.	Election of Director: Nancy Snyderman, M.D.,	Management	For	For
1G.	Election of Director: Jane E. Kiernan	Management	For	For
2.	To ratify the selection of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.	Management	For	For

AXSOME THERAPEUTICS INC

Security	05464T104	Meeting Type	Annual
Ticker Symbol	AXSM	Meeting Date	05-Jun-2020
Record Date	09-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Mark Saad		For	For
2.	Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm of the fiscal year ending in December 31, 2020.		Management	For	For

BEIGENE LTD

Security	07725L102	Meeting Type	Special
Ticker Symbol	BGNE	Meeting Date	27-Dec-2019
Record Date	27-Nov-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1	THAT the issuance of approximately 20.5% of the Company's outstanding shares upon closing to Amgen Inc. ("Amgen") be and is hereby approved, pursuant to the terms of the Share Purchase Agreement (the "Share Purchase Agreement") by and between the Company and Amgen.	Management	For	For
2	THAT the Collaboration Agreement (the "Collaboration Agreement") dated October 31, 2019 by and between the Company, BeiGene Switzerland GmbH and Amgen and the transactions contemplated thereunder be and are hereby approved.	Management	For	For
3	THAT the annual caps in relation to the Collaboration Agreement be and are hereby approved.	Management	For	For
4	THAT Anthony C. Hooper be and is hereby elected to serve as a Class III director of the Company until the 2022 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal, subject to and effective upon the closing of the transactions contemplated by the Share Purchase Agreement and the Collaboration Agreement.	Management	For	For

BEIGENE LTD

Security	07725L102	Meeting Type	Annual
Ticker Symbol	BGNE	Meeting Date	17-Jun-2020
Record Date	16-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1	Ordinary Resolution: THAT John V. Oyler be and is hereby re-elected to serve as a Class I director of the Company until the 2023 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
2	Ordinary Resolution: THAT Timothy Chen be and is hereby re-elected to serve as a Class I director of the Company until the 2023 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
3	Ordinary Resolution: THAT Jing-Shyh (Sam) Su be and is hereby re-elected to serve as a Class I director of the Company until the 2023 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
4	Ordinary Resolution: THAT the appointment of Ernst & Young Hua Ming LLP and Ernst & Young as the Company's independent registered public accounting firms for the fiscal year ending December 31, 2020 be and is hereby approved, ratified and confirmed.	Management	For	For
5	Ordinary Resolution: THAT the granting of a share issue mandate to the Board of Directors to issue, allot or deal with unissued ordinary shares and/or American Depositary Shares not exceeding 20% of the total number of issued ordinary shares of the Company as at the date of passing of this ordinary resolution up to the next annual general meeting of the Company be and is hereby approved.	Management	For	For
6	Ordinary Resolution: THAT the Company and its underwriters be and are hereby authorized, in their sole discretion, to allocate to each of Baker Bros. Advisors LP and Hillhouse Capital Management, Ltd. and parties affiliated with each of them (the "Existing Shareholders"), up to a maximum amount of shares in order to maintain the same shareholding percentage of each of the Existing Shareholders (based on the then- outstanding share capital of the Company) before and after the ...(due to space limits, see proxy material for full proposal).	Management	For	For
7	Ordinary Resolution: THAT the Company and its underwriters be and are hereby authorized, in their sole discretion, to allocate to Amgen Inc. ("Amgen"), up to a maximum amount of shares in order to maintain the same shareholding percentage of Amgen (based on the then-outstanding share capital of the Company) before and after the allocation of the corresponding securities issued pursuant to an offering conducted pursuant to the general mandate set forth in Resolution 5 for a period of ...(due to space limits, see proxy material for full proposal).	Management	For	For
8	Ordinary Resolution: THAT the Amendment No. 1 to the Second Amended and Restated 2016 Share Option and Incentive Plan to increase the number of authorized shares available for issuance by 57,200,000 ordinary shares and to extend the term of the plan through April 13, 2030, as disclosed in the Proxy Statement, be and is hereby approved.	Management	For	For
9	Ordinary Resolution: THAT, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, be and is hereby approved.	Management	For	For

BELLICUM PHARMACEUTICALS, INC.

Security	079481107	Meeting Type	Special
Ticker Symbol	BLCM	Meeting Date	15-Jan-2020
Record Date	22-Nov-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of a series of alternate amendments to the Company's Amended & Restated Certificate of Incorporation, to effect, at the Board's discretion: (i) a reverse split of the common stock, whereby each outstanding 5, 6, 7, 8, 9 or 10 shares of common stock would be combined & converted into one share of common stock; & (ii) for reverse splits in range of 1-for-5 to 1-for-10, a reduction in number of authorized shares of common stock from 200,000,000 to 80,000,000, 66,666,667, 57,142,858, 50,000,000, 44,444,445 or 40,000,000 shares, respectively.	Management	For	For
2.	Approval of an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000.	Management	For	For
3.	Approval of an amendment to the Company's 2019 Equity Incentive Plan, or the Amended 2019 Plan, to, among other things, increase the number of shares of common stock authorized for issuance under the 2019 Plan by 6,000,000 shares (before any adjustment for any reverse stock split).	Management	For	For
4.	Approval of the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of any of the foregoing proposals.	Management	For	For

BELLICUM PHARMACEUTICALS, INC.

Security	079481404	Meeting Type	Annual
Ticker Symbol	BLCM	Meeting Date	15-Jun-2020
Record Date	17-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Richard A. Fair		For	For
	2	James M. Daly		For	For
	3	Reid M. Huber, Ph.D		For	For
2.	To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 40,000,000 to 80,000,000.		Management	For	For
3.	To approve an amendment to the Company's 2019 Equity Incentive Plan, or the Amended 2019 Plan, to, among other things, increase the number of shares of common stock authorized for issuance under the 2019 Plan by 500,000 shares.		Management	For	For
4.	To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020.		Management	For	For
5.	To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.		Management	For	For
6.	To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.		Management	1 Year	Against

BIO-TECHNE CORP

Security	09073M104	Meeting Type	Annual
Ticker Symbol	TECH	Meeting Date	24-Oct-2019
Record Date	30-Aug-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To set the number of Directors at nine.	Management	For	For
2A.	Election of Director: Robert V. Baumgartner	Management	For	For
2B.	Election of Director: John L. Higgins	Management	For	For
2C.	Election of Director: Joseph D. Keegan	Management	For	For
2D.	Election of Director: Charles R. Kummeth	Management	For	For
2E.	Election of Director: Roeland Nusse	Management	For	For
2F.	Election of Director: Alpna Seth	Management	For	For
2G.	Election of Director: Randolph Steer	Management	For	For
2H.	Election of Director: Rupert Vessey	Management	For	For
2I.	Election of Director: Harold J. Wiens	Management	For	For
3.	Cast a non-binding vote on named executive officer compensation.	Management	For	For
4.	Ratify the appointment of the Company's independent registered public accounting firm for the 2020 fiscal year.	Management	For	For

BIOGEN INC.

Security	09062X103	Meeting Type	Annual
Ticker Symbol	BIIB	Meeting Date	03-Jun-2020
Record Date	06-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director for a one year term extending until the 2021 annual meeting: Alexander J. Denner	Management	For	For
1B.	Election of Director for a one year term extending until the 2021 annual meeting: Caroline D. Dorsa	Management	For	For
1C.	Election of Director for a one year term extending until the 2021 annual meeting: William A. Hawkins	Management	For	For
1D.	Election of Director for a one year term extending until the 2021 annual meeting: Nancy L. Leaming	Management	For	For
1E.	Election of Director for a one year term extending until the 2021 annual meeting: Jesus B. Mantas	Management	For	For
1F.	Election of Director for a one year term extending until the 2021 annual meeting: Richard C. Mulligan	Management	For	For
1G.	Election of Director for a one year term extending until the 2021 annual meeting: Robert W. Pangia	Management	For	For
1H.	Election of Director for a one year term extending until the 2021 annual meeting: Stelios Papadopoulos	Management	For	For
1I.	Election of Director for a one year term extending until the 2021 annual meeting: Brian S. Posner	Management	For	For
1J.	Election of Director for a one year term extending until the 2021 annual meeting: Eric K. Rowinsky	Management	For	For
1K.	Election of Director for a one year term extending until the 2021 annual meeting: Stephen A. Sherwin	Management	For	For
1L.	Election of Director for a one year term extending until the 2021 annual meeting: Michel Vounatsos	Management	For	For
2.	To ratify the selection of PricewaterhouseCoopers LLP as Biogen Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2020.	Management	For	For
3.	Say on Pay - To approve an advisory vote on executive compensation.	Management	For	For

BIOHAVEN PHARMACEUTICAL HLDG CO LTD

Security	G11196105	Meeting Type	Annual
Ticker Symbol	BHVN	Meeting Date	30-Apr-2020
Record Date	17-Mar-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director for a term expiring at the 2023 Annual Meeting of Shareholders: Dr. Declan Doogan	Management	For	For
1B.	Election of Director for a term expiring at the 2023 Annual Meeting of Shareholders: Dr. Vlad Coric	Management	For	For
2.	Ratification of appointment of Ernst & Young LLP as independent auditors for fiscal year 2020.	Management	For	For
3.	To approve, on a non-binding advisory basis, the compensation of the Named Executive Officers.	Management	For	For

BIOMARIN PHARMACEUTICAL INC.

Security	09061G101	Meeting Type	Annual
Ticker Symbol	BMRN	Meeting Date	27-May-2020
Record Date	30-Mar-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Jean-Jacques Bienaimé		For	For
	2	Elizabeth M. Anderson		For	For
	3	Willard Dere		For	For
	4	Michael Grey		For	For
	5	Elaine J. Heron		For	For
	6	Robert J. Hombach		For	For
	7	V. Bryan Lawlis		For	For
	8	Richard A. Meier		For	For
	9	David E.I. Pyott		For	For
	10	Dennis J. Slamon		For	For
2.	To ratify the selection of KPMG LLP as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2020.		Management	For	For
3.	To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.		Management	For	For

BLUEBIRD BIO, INC.

Security	09609G100	Meeting Type	Annual
Ticker Symbol	BLUE	Meeting Date	18-Jun-2020
Record Date	23-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class I Director: Nick Leschly	Management	For	For
1B.	Election of Class I Director: Douglas A. Melton, Ph.D.	Management	For	For
1C.	Election of Class I Director: Mark Vachon	Management	For	For
2.	To hold a non-binding advisory vote on the compensation paid to the Company's named executive officers.	Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.	Management	For	For

BLUEPRINT MEDICINES CORPORATION

Security	09627Y109	Meeting Type	Annual
Ticker Symbol	BPMC	Meeting Date	23-Jun-2020
Record Date	24-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Alexis Borisy		For	For
	2	Charles A. Rowland, Jr.		For	For
	3	Lonnel Coats		For	For
2.	To approve an advisory vote on named executive officer compensation.		Management	For	For
3.	Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For

BRIDGEBIO PHARMA INC

Security	10806X102	Meeting Type	Annual
Ticker Symbol	BBIO	Meeting Date	02-Jun-2020
Record Date	15-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	James C. Momtazee		For	For
	2	Richard H. Scheller PhD		For	For
2.	To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020.		Management	For	For
3.	To approve the Company's Amended and Restated 2019 Stock Option and Incentive Plan to, among other things, increase the number of shares of common stock reserved for issuance thereunder by 2,500,000 shares.		Management	For	For

BRISTOL-MYERS SQUIBB COMPANY

Security	110122108	Meeting Type	Annual
Ticker Symbol	BMY	Meeting Date	05-May-2020
Record Date	16-Mar-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Peter J. Arduini	Management	For	For
1B.	Election of Director: Robert Bertolini	Management	For	For
1C.	Election of Director: Michael W. Bonney	Management	For	For
1D.	Election of Director: Giovanni Caforio, M.D.	Management	For	For
1E.	Election of Director: Matthew W. Emmens	Management	For	For
1F.	Election of Director: Julia A. Haller, M.D.	Management	For	For
1G.	Election of Director: Dinesh C. Paliwal	Management	For	For
1H.	Election of Director: Theodore R. Samuels	Management	For	For
1I.	Election of Director: Vicki L. Sato, Ph.D.	Management	For	For
1J.	Election of Director: Gerald L. Storch	Management	For	For
1K.	Election of Director: Karen H. Vousden, Ph.D.	Management	For	For
1L.	Election of Director: Phyllis R. Yale	Management	For	For
2.	Advisory vote to approve the compensation of our Named Executive Officers.	Management	For	For
3.	Ratification of the appointment of an independent registered public accounting firm.	Management	For	For
4.	Shareholder Proposal on Separate Chair & CEO.	Shareholder	For	Against
5.	Shareholder Proposal on Shareholder Right to Act by Written Consent.	Shareholder	Against	For

CELLECTIS S.A.

Security	15117K103	Meeting Type	Annual
Ticker Symbol	CLLS	Meeting Date	29-Jun-2020
Record Date	22-May-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1	Approval of the financial statements for the financial year ended December 31, 2019.	Management	For	For
2	Approval of the consolidated financial statements for the financial year ended December 31, 2019.	Management	For	For
3	Allocation of income for the financial year ended December 31, 2019.	Management	For	For
4	Approval of the agreements referred to in articles L. 225- 38 and the following sections of the French commercial code.	Management	For	For
5	Setting the amount of the total compensation (directors fees) to be granted to the non-executive directors.	Management	For	For
6	Renewal of the mandate of a member of the Board of Directors of Mrs. Annick Schwebig.	Management	For	For
7	Renewal of the mandate of a member of the Board of Directors of Mr. Laurent Arthaud.	Management	For	For
8	Renewal of the mandate of a member of the Board of Directors of Mr. Pierre Bastid.	Management	For	For
9	Renewal of the mandate of a member of the Board of Directors of Mr. Rainer Boehm.	Management	For	For
10	Renewal of the mandate of a member of the Board of Directors of Mr. Hervé Hoppenot.	Management	For	For
11	Authorization to be given to the board of directors to buy back Company shares.	Management	For	For
12	Authorization to be given to the board of directors for the ...(due to space limits, see proxy material for full proposal).	Management	For	For
13	Delegation of authority to be granted to the board of directors ...(due to space limits, see proxy material for full proposal).	Management	For	For
14	Delegation of authority to be granted to the board of directors ...(due to space limits, see proxy material for full proposal).	Management	For	For
15	Delegation of authority to be granted to the board of directors ...(due to space limits, see proxy material for full proposal).	Management	For	For
16	Delegation of authority to be granted to the board of directors ...(due to space limits, see proxy material for full proposal).	Management	For	For
17	Delegation of authority to be granted to the board of directors ...(due to space limits, see proxy material for full proposal).	Management	For	For
18	Delegation of authority to be granted to the board of directors ...(due to space limits, see proxy material for full proposal).	Management	For	For
19	Delegation of authority to be granted to the board of directors ...(due to space limits, see proxy material for full proposal).	Management	For	For
20	Delegation granted to the board of directors to increase the ...(due to space limits, see proxy material for full proposal).	Management	For	For
21	Overall limitations to the amount of issuances made under the ...(due to space limits, see proxy material for full proposal).	Management	For	For
22	Delegation of authority to be granted to the board of directors ...(due to space limits, see proxy material for full proposal).	Management	For	For
23	Authorization to be given to the board of directors to grant options to subscribe or purchase Company's shares.	Management	For	For
24	Authorization be given to the board of directors for the ...(due to space limits, see proxy material for full proposal).	Management	For	For
25	Delegation of authority to be granted to the board of directors ...(due to space limits, see proxy material for full proposal).	Management	For	For
26	Overall limitations to the amount of issues made under the 23rd resolution, 24th resolution and the 25th resolution above.	Management	For	For
27	Amendment of article 12 of the articles of association "meeting ...(due to space limits, see proxy material for full proposal).	Management	For	For
28	Amendment of Article 18 of the Articles of Association "General ...(due to space limits, see proxy material for full proposal).	Management	For	For
29	Delegation to be granted to the board of directors for the ...(due to space limits, see proxy material for full proposal).	Management	Against	For

CELLECTIS S.A.

Security	15117K103	Meeting Type	Annual
Ticker Symbol	CLLS	Meeting Date	29-Jun-2020
Record Date	11-Jun-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1	Approval of the financial statements for the financial year ended December 31, 2019.	Management	For	For
2	Approval of the consolidated financial statements for the financial year ended December 31, 2019.	Management	For	For
3	Allocation of income for the financial year ended December 31, 2019.	Management	For	For
4	Approval of the agreements referred to in articles L. 225- 38 and the following sections of the French commercial code.	Management	For	For
5	Setting the amount of the total compensation (directors fees) to be granted to the non-executive directors.	Management	For	For
6	Renewal of the mandate of a member of the Board of Directors of Mrs. Annick Schwebig.	Management	For	For
7	Renewal of the mandate of a member of the Board of Directors of Mr. Laurent Arthaud.	Management	For	For
8	Renewal of the mandate of a member of the Board of Directors of Mr. Pierre Bastid.	Management	For	For
9	Renewal of the mandate of a member of the Board of Directors of Mr. Rainer Boehm.	Management	For	For
10	Renewal of the mandate of a member of the Board of Directors of Mr. Hervé Hoppenot.	Management	For	For
11	Authorization to be given to the board of directors to buy back Company shares.	Management	For	For
12	Authorization to be given to the board of directors for the ...(due to space limits, see proxy material for full proposal).	Management	For	For
13	Delegation of authority to be granted to the board of directors ...(due to space limits, see proxy material for full proposal).	Management	For	For
14	Delegation of authority to be granted to the board of directors ...(due to space limits, see proxy material for full proposal).	Management	For	For
15	Delegation of authority to be granted to the board of directors ...(due to space limits, see proxy material for full proposal).	Management	For	For
16	Delegation of authority to be granted to the board of directors ...(due to space limits, see proxy material for full proposal).	Management	For	For
17	Delegation of authority to be granted to the board of directors ...(due to space limits, see proxy material for full proposal).	Management	For	For
18	Delegation of authority to be granted to the board of directors ...(due to space limits, see proxy material for full proposal).	Management	For	For
19	Delegation of authority to be granted to the board of directors ...(due to space limits, see proxy material for full proposal).	Management	For	For
20	Delegation granted to the board of directors to increase the ...(due to space limits, see proxy material for full proposal).	Management	For	For
21	Overall limitations to the amount of issuances made under the ...(due to space limits, see proxy material for full proposal).	Management	For	For
22	Delegation of authority to be granted to the board of directors ...(due to space limits, see proxy material for full proposal).	Management	For	For
23	Authorization to be given to the board of directors to grant options to subscribe or purchase Company's shares.	Management	For	For
24	Authorization be given to the board of directors for the ...(due to space limits, see proxy material for full proposal).	Management	For	For
25	Delegation of authority to be granted to the board of directors ...(due to space limits, see proxy material for full proposal).	Management	For	For
26	Overall limitations to the amount of issues made under the 23rd resolution, 24th resolution and the 25th resolution above.	Management	For	For
27	Amendment of article 12 of the articles of association "meeting ...(due to space limits, see proxy material for full proposal).	Management	For	For
28	Amendment of Article 18 of the Articles of Association "General ...(due to space limits, see proxy material for full proposal).	Management	For	For
29	Delegation to be granted to the board of directors for the ...(due to space limits, see proxy material for full proposal).	Management	Against	For

CIDARA THERAPEUTICS, INC.

Security	171757107	Meeting Type	Annual
Ticker Symbol	CDTX	Meeting Date	25-Jun-2020
Record Date	27-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director for terms expiring in 2023: Daniel Burgess	Management	For	For
1B.	Election of Director for terms expiring in 2023: Theodore R. Schroeder	Management	For	For
2.	Ratify the selection of Ernst & Young LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2020.	Management	For	For

CLEARSIDE BIOMEDICAL, INC.

Security	185063104	Meeting Type	Annual
Ticker Symbol	CLSD	Meeting Date	18-Jun-2020
Record Date	23-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Jeffrey L. Edwards		For	For
	2	Clay B. Thorp		For	For
2.	RATIFICATION OF THE SELECTION OF ERNST & YOUNG LLP AS INDEPENDENT AUDITORS FOR THE FISCAL YEAR ENDING DECEMBER 31, 2020.		Management	For	For

COHERUS BIOSCIENCES INC

Security	19249H103	Meeting Type	Annual
Ticker Symbol	CHRS	Meeting Date	22-May-2020
Record Date	31-Mar-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Dennis M. Lanfear		For	For
	2	Mats Wahlström		For	For
	3	James I. Healy, MD, PhD		For	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For
3.	A non-binding, advisory resolution to approve the compensation of our named executive officers (a "Say-on-Pay" vote).		Management	For	For

CRISPR THERAPEUTICS AG

Security	H17182108	Meeting Type	Annual
Ticker Symbol	CRSP	Meeting Date	11-Jun-2020
Record Date	13-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.	The approval of the annual report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2019.	Management	For	For
2.	The approval of the appropriation of financial results.	Management	For	For
3.	The discharge of the members of the Board of Directors and Executive Committee.	Management	For	For
4A.	Re-election of Rodger Novak, M.D., as member and Chairman	Management	For	For
4B.	Re-election of Samarth Kulkarni, Ph.D.	Management	For	For
4C.	Re-election of Ali Behbahani, M.D.	Management	For	For
4D.	Re-election of Bradley Bolzon, Ph.D.	Management	For	For
4E.	Re-election of Simeon J. George, M.D.	Management	For	For
4F.	Re-election of John T. Greene	Management	For	For
4G.	Re-election of Katherine A. High, M.D.	Management	For	For
4H.	Election of Douglas A. Treco, Ph.D.	Management	For	For
5A.	Election of the member of the Compensation Committee: Ali Behbahani, M.D.	Management	For	For
5B.	Re-election of the member of the Compensation Committee: Simeon J. George, M.D.	Management	For	For
5C.	Re-election of the member of the Compensation Committee: John T. Greene	Management	For	For
6A.	Binding vote on total non-performance-related compensation for members of the Board of Directors from the 2020 Annual General Meeting to the 2021 Annual General Meeting of Shareholders.	Management	For	For
6B.	Binding vote on equity for members of the Board of Directors from the 2020 Annual General Meeting to the 2021 Annual General Meeting of Shareholders.	Management	For	For
6C.	Binding vote on total non-performance-related compensation for members of the Executive Committee from July 1, 2020 to June 30, 2021.	Management	For	For
6D.	Binding vote on total variable compensation for members of the Executive Committee for the current year ending December 31, 2020.	Management	For	For
6E.	Binding vote on equity for members of the Executive Committee from the 2020 Annual General Meeting to the 2021 Annual General Meeting of Shareholders.	Management	For	For
7.	The approval of an increase in the Conditional Share Capital for Employee Benefit Plans.	Management	For	For
8.	The approval of an Amendment to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan.	Management	Against	Against
9.	The approval of increasing the maximum number of authorized share capital and extending the date by which the Board of Directors may increase share capital.	Management	For	For
10.	The re-election of the independent voting rights representative.	Management	For	For
11.	The re-election of the auditors.	Management	For	For
12.	The transaction of any other business that may properly come before the 2020 Annual General Meeting or any adjournment or postponement thereof.	Management	For	For

CURASEN THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	6-Jan-2020
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Amendment to CuraSen Therapeutics, Inc. A&R 2016 Equity Incentive Plan	Management	For	For
2.	General Authority and ratification	Management	For	For

CYMABAY THERAPEUTICS INC

Security	23257D103	Meeting Type	Annual
Ticker Symbol	CBAY	Meeting Date	23-Jun-2020
Record Date	28-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Sujal Shah		For	For
	2	Caroline Loewy		For	For
	3	Paul F. Truex		For	For
	4	Kurt von Emster		For	For
	5	Robert J. Wills, Ph.D.		For	For
2.	Ratification of selection, by the Audit Committee of the Board, of Ernst & Young LLP as the independent registered public accounting firm of CymaBay for its fiscal year ending December 31, 2020.		Management	For	For
3.	Advisory vote to approve the compensation of our named executive officers as disclosed in the proxy statement.		Management	For	For
4.	To vote on an amendment to the CymaBay Amended and Restated Certificate of Incorporation to increase the number of authorized shares of our common stock from 100,000,000 shares to 200,000,000 shares.		Management	For	For

DECIPHER BIOSCIENCES, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	16-Sep-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Amendment of 2018 Equity Incentive Plan	Management	For	For
2.	General Authorizing Resolution	Management	For	For

DECIPHER BIOSCIENCES, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	14-May-2020
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Amendment and Restatement of Certification of Incorporation	Management	For	For
2.	Series 4 Preferred Stock and Note Financing	Management	For	For
3.	Amendment of 2018 Equity Incentive Plan	Management	For	For
4.	General Authorizing Resolution	Management	For	For

DECIPHER PHARMACEUTICALS, INC.

Security	24344T101	Meeting Type	Annual
Ticker Symbol	DCPH	Meeting Date	10-Jun-2020
Record Date	13-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Patricia L. Allen		For	For
	2	Edward J. Benz, Jr., MD		For	For
	3	Dennis L. Walsh		For	For
2.	To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2020.		Management	For	For

DYNACURE

Security	N/A	Meeting Type	Annual Meeting
Ticker Symbol	N/A	Meeting Date	16-Jun-2020
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Waiver of the period and form of prior notice	Management	For	For
2.	Approval of the financial statements for the financial year ended on December 31, 2019; Discharge to the Chairman for his duties during the past financial year	Management	For	For
3.	Allocation of the result of the financial year ended on December 31, 2019	Management	For	For
4.	Review and approval of the Statutory Auditors' special report on the agreements referred to in Article L. 227-10 of the French commercial code	Management	For	For
5.	Renewal of the terms of office of Brett Monia, Raphael Wisniewski, Remi Droller and Georges Gemayel, in their capacity as members of the Supervisory Board	Management	For	For
6.	Acknowledgement of the resignation of Caroline Dreyer and Philippe Guinot from their duties as observers of the Supervisory Board and appointment of new observers of the Supervisory Board	Management	For	For
7.	Powers to carry out formalities	Management	For	For

EDITAS MEDICINE, INC.

Security	28106W103	Meeting Type	Annual
Ticker Symbol	EDIT	Meeting Date	10-Jun-2020
Record Date	15-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	James C. Mullen		For	For
	2	Akshay Vaishnaw, M.D.		For	For
2.	To approve, on an advisory basis, named executive officer compensation.		Management	For	For
3.	To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For

EIDOS THERAPEUTICS INC.

Security	28249H104	Meeting Type	Annual
Ticker Symbol	EIDX	Meeting Date	27-May-2020
Record Date	01-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Neil Kumar, Ph.D.		For	For
	2	Eric Aguiar, M.D.		For	For
	3	William Lis		For	For
	4	Ali Satvat		For	For
	5	Rajeev Shah		For	For
	6	Uma Sinha, Ph.D.		For	For
2.	To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020.		Management	For	For
3.	To approve an amendment and restatement of the Company's Amended and Restated 2018 Stock Option and Incentive Plan to, among other things, increase the number of shares of common stock reserved for issuance thereunder by 1,500,000 shares.		Management	For	For

ENDO INTERNATIONAL PLC

Security	G30401106	Meeting Type	Annual
Ticker Symbol	ENDP	Meeting Date	11-Jun-2020
Record Date	13-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Paul V. Campanelli	Management	For	For
1B.	Election of Director: Blaise Coleman	Management	For	For
1C.	Election of Director: Mark G. Barberio	Management	For	For
1D.	Election of Director: Shane M. Cooke	Management	For	For
1E.	Election of Director: Nancy J. Hutson, Ph.D.	Management	For	For
1F.	Election of Director: Michael Hyatt	Management	For	For
1G.	Election of Director: Roger H. Kimmel	Management	For	For
1H.	Election of Director: William P. Montague	Management	For	For
2.	To approve, by advisory vote, named executive officer compensation.	Management	For	For
3.	To approve the Endo International plc Amended and Restated 2015 Stock Incentive Plan.	Management	For	For
4.	To renew the Board's existing authority to issue shares under Irish law.	Management	For	For
5.	To renew the Board's existing authority to opt-out of statutory pre-emption rights under Irish law.	Management	For	For
6.	To approve the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2020 and to authorize the Board of Directors, acting through the Audit Committee, to determine the independent registered public accounting firm's remuneration.	Management	For	For

EPIZYME, INC.

Security	29428V104	Meeting Type	Annual
Ticker Symbol	EPZM	Meeting Date	29-May-2020
Record Date	07-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Andrew R. Allen, MD PhD		For	For
	2	Kenneth Bate		For	For
	3	Robert B. Bazemore, Jr.		For	For
	4	Victoria Richon, Ph.D.		For	For
2.	Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For
3.	Advisory Vote on Executive Compensation.		Management	For	For
4.	Approval of an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 125,000,000 to 150,000,000.		Management	For	For

ESPERION THERAPEUTICS INC

Security	29664W105	Meeting Type	Annual
Ticker Symbol	ESPR	Meeting Date	28-May-2020
Record Date	31-Mar-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class I Director: Daniel Janney	Management	For	For
1B.	Election of Class I Director: Tim M. Mayleben	Management	For	For
1C.	Election of Class I Director: Mark E. McGovern, M.D., FACC, FACP	Management	For	For
1D.	Election of Class I Director: Tracy M. Woody	Management	For	For
2.	To approve the advisory resolution on the compensation of our named executive officers	Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020	Management	For	For
4.	To approve the 2020 Employee Stock Purchase Plan	Management	For	For

EXACT SCIENCES CORPORATION

Security	30063P105	Meeting Type	Annual
Ticker Symbol	EXAS	Meeting Date	23-Jul-2020
Record Date	01-Jun-2020

Item	Proposal		Proposed  by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Eli Casdin		For	For
	2	James E. Doyle		For	For
	3	Freda Lewis-Hall		For	For
	4	Kathleen Sebelius		For	For
2.	To ratify the appointment of PricewaterhouseCoopers, LLP as the Company's independent registered public accounting firm for 2020.		Management	For	For
3.	To approve on an advisory basis the compensation of the Company's named executive officers.		Management	For	For
4.	To approve an amendment to the Company's Certificate of Incorporation increasing the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares.		Management	For	For

EXELIXIS, INC.

Security	30161Q104	Meeting Type	Annual
Ticker Symbol	EXEL	Meeting Date	20-May-2020
Record Date	23-Mar-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Charles Cohen, Ph.D.	Management	For	For
1B.	Election of Director: Carl B. Feldbaum, Esq.	Management	For	For
1C.	Election of Director: Maria C. Freire, Ph.D.	Management	For	For
1D.	Election of Director: Alan M. Garber, M.D., Ph.D.	Management	For	For
1E.	Election of Director: Vincent T. Marchesi, M.D., Ph.D.	Management	For	For
1F.	Election of Director: Michael M. Morrissey, Ph.D.	Management	For	For
1G.	Election of Director: Stelios Papadopoulos, Ph.D.	Management	For	For
1H.	Election of Director: George Poste, DVM, Ph.D., FRS	Management	For	For
1I.	Election of Director: Julie Anne Smith	Management	For	For
1J.	Election of Director: Lance Willsey, M.D.	Management	For	For
1K.	Election of Director: Jack L. Wyszomierski	Management	For	For
2.	To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis' independent registered public accounting firm for the fiscal year ending January 1, 2021.	Management	For	For
3.	To amend and restate the Exelixis 2017 Equity Incentive Plan to, among other things, increase the number of shares authorized for issuance by 21,000,000 shares.	Management	For	For
4.	To approve, on an advisory basis, the compensation of Exelixis' named executive officers, as disclosed in the accompanying Proxy Statement.	Management	For	For

FATE THERAPEUTICS, INC.

Security	31189P102	Meeting Type	Annual
Ticker Symbol	FATE	Meeting Date	01-May-2020
Record Date	06-Mar-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Robert S Epstein MD M.S		For	For
	2	John D Mendlein PhD. JD		For	For
	3	Karin Jooss, Ph.D.		For	For
2.	To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020.		Management	For	For
3.	To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement.		Management	For	For

FIBROGEN, INC.

Security	31572Q808	Meeting Type	Annual
Ticker Symbol	FGEN	Meeting Date	04-Jun-2020
Record Date	09-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class III Director to hold office until the 2023 Annual Meeting of Stockholders: Enrique Conterno	Management	For	For
1B.	Election of Class III Director to hold office until the 2023 Annual Meeting of Stockholders: Thomas F. Kearns, Jr.	Management	For	For
1C.	Election of Class III Director to hold office until the 2023 Annual Meeting of Stockholders: Kalevi Kurkijärvi, Ph.D.	Management	For	For
1D.	Election of Class III Director to hold office until the 2023 Annual Meeting of Stockholders: Gerald Lema	Management	For	For
2.	To approve, on an advisory basis, the compensation of FibroGen's named executive officers, as disclosed in the proxy statement.	Management	For	For
3.	To ratify the selection of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of FibroGen for the year ending December 31, 2020.	Management	For	For

FOAMIX PHARMACEUTICALS LTD

Security	M46135105	Meeting Type	Special
Ticker Symbol	FOMX	Meeting Date	06-Feb-2020
Record Date	06-Jan-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval and adoption of (i) the Agreement and Plan of Merger dated November 10, 2019 (as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of December 4, 2019, and as may be amended from time to time, the "Merger Agreement"), by and among Menlo Therapeutics Inc. ("Menlo"), Giants Merger Subsidiary Ltd., an Israeli company and a wholly-owned subsidiary of Menlo ("Merger Sub") and Foamix Pharmaceuticals Ltd. ("Foamix"); (ii) the merger of Merger Sub with and into ...(due to space limits, see proxy material for full proposal).	Management	For	For
1A.	By checking the box marked "FOR," the undersigned hereby confirms that he, she, or it is not Menlo, Merger Sub, or a Menlo Related Person. A "Menlo Related Person" is (a) a person holding, directly or indirectly, either (i) 25% or more of the voting rights of Menlo or Merger Sub, or (ii) the right to appoint 25% or more of the directors of Menlo or Merger Sub, (b) a person or entity acting on behalf of Menlo, Merger Sub or a person described in subsection (a) above, or (c) one of such ...(due to space limits, see proxy material for full proposal).	Management	For	For
2.	Approval, on a non-binding, advisory basis, in accordance with the rules under the Securities Exchange Act of 1934, as amended, of certain compensation that may be paid or become payable to the named executive officers of Foamix in connection with the Merger and contemplated by the Merger Agreement.	Management	For	For

GALERA THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	9-Jul-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Election of Lawrence Alleva to the Board of Directors	Management	For	For
2.	General Enabling Resolutions	Management	For	For

GALERA THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	16-Oct-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Form of Lock-Up Agreement	Management	For	For

GALERA THERAPEUTICS, INC.

Security	36338D108	Meeting Type	Annual
Ticker Symbol	GRTX	Meeting Date	09-Jun-2020
Record Date	16-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Michael Powell, Ph.D.		For	For
	2	Linda West		For	For
2.	To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For

GENMAB A S

Security	372303206	Meeting Type	Annual
Ticker Symbol	GMAB	Meeting Date	26-Mar-2020
Record Date	21-Feb-2020

Item	Proposal	Proposed by	Vote	For/Against Management
2.	Adoption of the audited Annual Report and discharge of the Board of Directors and the Executive Management.	Management	For	For
3.	Decision as to the distribution of profit according to the adopted Annual Report.	Management	For	For
4A.	Re-election of Director: Deirdre P. Connelly	Management	For	For
4B.	Re-election of Director: Pernille Erenbjerg	Management	For	For
4C.	Re-election of Director: Rolf Hoffmann	Management	For	For
4D.	Re-election of Director: Dr. Paolo Paoletti	Management	For	For
4E.	Re-election of Director: Dr. Anders Gersel Pedersen	Management	For	For
4F.	Election of Director: Jonathan Peacock	Management	For	For
5.	Re-election of auditor: PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab.	Management	For	For
6A.	Proposals from the Board of Directors: Adoption of the Remuneration Policy for the Board of Directors and the Executive Management.	Management	For	For
6B.	Proposals from the Board of Directors: Approval of the Board of Directors' remuneration for 2020.	Management	For	For
6C.	Proposals from the Board of Directors: Amendment of Article 6 (provider of share registration services).	Management	For	For
7.	Authorization of the chairman of the General Meeting to register resolutions passed by the General Meeting.	Management	For	For

GILEAD SCIENCES, INC.

Security	375558103	Meeting Type	Annual
Ticker Symbol	GILD	Meeting Date	06-May-2020
Record Date	13-Mar-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Jacqueline K. Barton, Ph.D.	Management	For	For
1B.	Election of Director: Sandra J. Horning, M.D.	Management	For	For
1C.	Election of Director: Kelly A. Kramer	Management	For	For
1D.	Election of Director: Kevin E. Lofton	Management	For	For
1E.	Election of Director: Harish Manwani	Management	For	For
1F.	Election of Director: Daniel P. O'Day	Management	For	For
1G.	Election of Director: Richard J. Whitley, M.D.	Management	For	For
1H.	Election of Director: Per Wold-Olsen	Management	For	For
2.	To ratify the selection of Ernst & Young LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of Gilead for the fiscal year ending December 31, 2020.	Management	For	For
3.	To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.	Management	For	For
4.	To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board adopt a policy that the Chairperson of the Board of Directors be an independent director.	Shareholder	For	Against
5.	To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board eliminate the ownership threshold for stockholders to request a record date to take action by written consent.	Shareholder	For	Against

GLOBAL BLOOD THERAPEUTICS, INC.

Security	37890U108	Meeting Type	Annual
Ticker Symbol	GBT	Meeting Date	17-Jun-2020
Record Date	22-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Willie L. Brown, Jr.		For	For
	2	Philip A. Pizzo, M.D.		For	For
	3	Wendy Yarno		For	For
2.	Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement.		Management	For	For
3.	Ratification of the appointment of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020.		Management	For	For

GUARDANT HEALTH, INC.

Security	40131M109	Meeting Type	Annual
Ticker Symbol	GH	Meeting Date	12-Jun-2020
Record Date	20-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class II Director: Ian Clark	Management	For	For
1B.	Election of Class II Director: Samir Kaul	Management	For	For
2.	Ratification of the appointment of Ernst & Young LLP as Guardant Health, Inc.'s independent registered public accounting firm for the year ending December 31, 2020.	Management	For	For
3.	Advisory vote on the frequency of stockholder advisory votes regarding the compensation of our named executive officers.	Management	1 Year	For

GW PHARMACEUTICALS PLC

Security	36197T103	Meeting Type	Annual
Ticker Symbol	GWPH	Meeting Date	26-May-2020
Record Date	31-Mar-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To re-elect Dr. Geoffrey W. Guy as a Director	Management	For	For
2.	To re-elect Cabot Brown as a Director	Management	For	For
3.	To approve the 2020 Long Term Incentive Plan	Management	For	For
4.	To approve the Directors' Remuneration Report	Management	For	For
5.	To approve the compensation of the Company's named executive officers	Management	For	For
6.	To ratify the appointment of Deloitte and Touche LLP as the Company's US public accounting firm	Management	For	For
7.	To re-appoint Deloitte LLP as the UK Auditor	Management	For	For
8.	To authorise the Directors to determine the Auditors' remuneration	Management	For	For
9.	To receive, consider and adopt the Directors' and Auditors' Reports and Statement of Accounts for the 12- month period ended 31 December 2019 and note that the Directors do not recommend the payment of a dividend	Management	For	For
10.	To authorise the Directors to allot shares pursuant to Section 551 of the Companies Act 2006 (the "2006 Act") such authority to be valid up to 26 May 2021	Management	For	For
11.	Subject to the passing of Resolution 10, to authorise the Directors to allot equity securities, under Section 570 of the 2006 Act as if Section 561(1) of the 2006 Act did not apply to such allotment	Management	For	For

HERON THERAPEUTICS, INC.

Security	427746102	Meeting Type	Annual
Ticker Symbol	HRTX	Meeting Date	17-Jun-2020
Record Date	20-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Kevin Tang	Management	For	For
1B.	Election of Director: Barry Quart, Pharm.D.	Management	For	For
1C.	Election of Director: Stephen Davis	Management	For	For
1D.	Election of Director: Craig Johnson	Management	For	For
1E.	Election of Director: Kimberly Manhard	Management	For	For
1F.	Election of Director: John Poyhonen	Management	For	For
1G.	Election of Director: Christian Waage	Management	For	For
2.	To ratify the appointment of OUM & Co. LLP as the Company's independent registered public accounting firm for the year ending December 31, 2020.	Management	For	For
3.	To approve, on an advisory basis, compensation paid to the Company's Named Executive Officers during the year ended December 31, 2019.	Management	For	For

HORIZON THERAPEUTICS PLC

Security	G46188101	Meeting Type	Annual
Ticker Symbol	HZNP	Meeting Date	30-Apr-2020
Record Date	25-Feb-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class III Director: Gino Santini	Management	For	For
1B.	Election of Class III Director: James Shannon, M.D.	Management	For	For
1C.	Election of Class III Director: Timothy Walbert	Management	For	For
2.	Approval of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020 and authorization of the Audit Committee to determine the auditors' remuneration.	Management	For	For
3.	Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in the Proxy Statement.	Management	For	For
4.	Authorization for us and/or any of our subsidiaries to make market purchases or overseas market purchases of our ordinary shares.	Management	For	For
5.	Approval of the 2020 Equity Incentive Plan.	Management	For	For
6.	Approval of the 2020 Employee Share Purchase Plan.	Management	For	For

IDEXX LABORATORIES, INC.

Security	45168D104	Meeting Type	Annual
Ticker Symbol	IDXX	Meeting Date	06-May-2020
Record Date	09-Mar-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Rebecca M. Henderson, PhD	Management	For	For
1B.	Election of Director: Lawrence D. Kingsley	Management	For	For
1C.	Election of Director: Sophie V. Vandebroek, PhD	Management	For	For
2.	Ratification of Appointment of Independent Registered Public Accounting Firm. To ratify the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year (Proposal Two).	Management	For	For
3.	Advisory Vote on Executive Compensation. To approve a nonbinding advisory resolution on the Company's executive compensation (Proposal Three).	Management	For	For

ILLUMINA, INC.

Security	452327109	Meeting Type	Annual
Ticker Symbol	ILMN	Meeting Date	27-May-2020
Record Date	30-Mar-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Caroline Dorsa	Management	For	For
1B.	Election of Director: Robert S. Epstein, M.D.	Management	For	For
1C.	Election of Director: Scott Gottlieb, M.D.	Management	For	For
1D.	Election of Director: Philip W. Schiller	Management	For	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending January 3, 2021.	Management	For	For
3.	To approve, on an advisory basis, the compensation of the named executive officers as disclosed in the Proxy Statement.	Management	For	For
4.	To approve, on an advisory basis, a stockholder proposal regarding political disclosures.	Shareholder	Against	For

ILLUMINOSS MEDICAL, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	1-Jul-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Amendment to Sixth Amended and Restated Certification of Incorporation	Management	For	For
2.	Amendment No. 5 to Amended and Restated Secured Note and Warrant Purchase Agreement	Management	For	For
3.	General Authorizing Resolution	Management	For	For

ILLUMINOSS MEDICAL, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	21-Apr-2020
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Merger; Agreement and Plan of Merger	Management	For	For
2.	General Ratification and Authorization	Management	For	For

IMMUNOGEN, INC.

Security	45253H101	Meeting Type	Annual
Ticker Symbol	IMGN	Meeting Date	17-Jun-2020
Record Date	13-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	To fix the number of members of the Board of Directors at seven (7).		Management	For	For
2.	DIRECTOR		Management
	1	Stephen C. McCluski		For	For
	2	Richard J. Wallace		For	For
	3	Mark Goldberg, MD		For	For
	4	Dean J. Mitchell		For	For
	5	Kristine Peterson		For	For
	6	Mark J. Enyedy		For	For
	7	Stuart A. Arbuckle		For	For
3.	To approve an amendment to our Restated Articles of Organization to increase the number of authorized shares of common stock from 200,000,000 to 300,000,000.		Management	For	For
4.	To approve, on an advisory basis, the compensation paid to our named executive officers, as disclosed in our proxy statement.		Management	For	For

IMMUNOMEDICS, INC.

Security	452907108	Meeting Type	Annual
Ticker Symbol	IMMU	Meeting Date	18-Jun-2020
Record Date	24-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Dr. Behzad Aghazadeh	Management	For	For
1.2	Election of Director: Robert Azelby	Management	For	For
1.3	Election of Director: Dr. Charles M. Baum	Management	For	For
1.4	Election of Director: Scott Canute	Management	For	For
1.5	Election of Director: Barbara G. Duncan	Management	For	For
1.6	Election of Director: Peter Barton Hutt	Management	For	For
1.7	Election of Director: Dr. Khalid Islam	Management	For	For
1.8	Election of Director: Harout Semerjian	Management	For	For
2.	Proposal to approve the compensation of our named executive officers.	Management	For	For
3.	Proposal to approve the amendment and restatement of the Company's certificate of incorporation.	Management	For	For
4.	Proposal to approve the amendment and restatement of the Company's 2014 Long-Term Incentive Plan.	Management	For	For
5.	Proposal to approve and adopt the Company's 2020 Employee Stock Purchase Plan.	Management	For	For
6.	Proposal to ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.	Management	For	For

INCYTE CORPORATION

Security	45337C102	Meeting Type	Annual
Ticker Symbol	INCY	Meeting Date	26-May-2020
Record Date	01-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Julian C. Baker	Management	For	For
1.2	Election of Director: Jean-Jacques Bienaimé	Management	For	For
1.3	Election of Director: Paul J. Clancy	Management	For	For
1.4	Election of Director: Wendy L. Dixon	Management	For	For
1.5	Election of Director: Jacqualyn A. Fouse	Management	For	For
1.6	Election of Director: Paul A. Friedman	Management	For	For
1.7	Election of Director: Edmund P. Harrigan	Management	For	For
1.8	Election of Director: Katherine A. High	Management	For	For
1.9	Election of Director: Hervé Hoppenot	Management	For	For
2.	To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.	Management	For	For
3.	To approve an amendment to the Company's 1997 Employee Stock Purchase Plan.	Management	For	For
4.	To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2020.	Management	For	For
5.	To vote on a stockholder proposal, if properly presented, described in more detail in the proxy statement.	Shareholder	Against	For

INOGEN, INC.

Security	45780L104	Meeting Type	Annual
Ticker Symbol	INGN	Meeting Date	11-May-2020
Record Date	13-Mar-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Heath Lukatch, Ph.D.		For	For
	2	Raymond Huggenberger		For	For
2.	To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending December 31, 2020.		Management	For	For
3.	Approval on an advisory basis of our executive compensation for the fiscal year ended December 31, 2019.		Management	For	For

INSMED INCORPORATED

Security	457669307	Meeting Type	Annual
Ticker Symbol	INSM	Meeting Date	12-May-2020
Record Date	18-Mar-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Clarissa Desjardins PhD		For	For
	2	David W.J. McGirr		For	For
	3	E. McKee Anderson		For	For
2.	Advisory vote on the 2019 compensation of our named executive officers.		Management	For	For
3.	Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for Insmed Incorporated for the year ending December 31, 2020.		Management	For	For
4.	Approval of an amendment to the Insmed Incorporated 2019 Incentive Plan.		Management	For	For

INTELLIA THERAPEUTICS, INC.

Security	45826J105	Meeting Type	Annual
Ticker Symbol	NTLA	Meeting Date	18-Jun-2020
Record Date	20-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Jean-François Formela		For	For
	2	Jesse Goodman, M.D MPH		For	For
2.	Ratification of the appointment of Deloitte & Touche LLP as Intellia's independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For
3.	Approve, on an advisory basis, the compensation of the named executive officers.		Management	For	For

INTERCEPT PHARMACEUTICALS, INC.

Security	45845P108	Meeting Type	Annual
Ticker Symbol	ICPT	Meeting Date	28-May-2020
Record Date	06-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Paolo Fundarò	Management	For	For
1B.	Election of Director: Mark Pruzanski, M.D.	Management	For	For
1C.	Election of Director: Srinivas Akkaraju, M.D., Ph.D.	Management	For	For
1D.	Election of Director: Luca Benatti, Ph.D.	Management	For	For
1E.	Election of Director: Daniel Bradbury	Management	For	For
1F.	Election of Director: Keith Gottesdiener, M.D.	Management	For	For
1G.	Election of Director: Nancy Miller-Rich	Management	For	For
1H.	Election of Director: Gino Santini	Management	For	For
1I.	Election of Director: Glenn Sblendorio	Management	For	For
1J.	Election of Director: Daniel Welch	Management	For	For
2.	FOR the approval of an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 45,000,000 to 90,000,000.	Management	For	For
3.	FOR the approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.	Management	For	For
4.	FOR the ratification of the appointment of KPMG LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2020.	Management	For	For

INTRA-CELLULAR THERAPIES INC

Security	46116X101	Meeting Type	Annual
Ticker Symbol	ITCI	Meeting Date	27-May-2020
Record Date	06-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Richard Lerner, M.D.		For	For
2.	To approve an amendment and restatement of the Company's 2018 Equity Incentive Plan.		Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For
4.	To approve by an advisory vote the compensation of the Company's named executive officers, as disclosed in the proxy statement.		Management	For	For

IO LIGHT HOLDINGS INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	29-Apr-2020
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Shareholder rights	Management	For	For

IONIS PHARMACEUTICALS, INC.

Security	462222100	Meeting Type	Annual
Ticker Symbol	IONS	Meeting Date	04-Jun-2020
Record Date	06-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Joseph Wender		For	For
	2	B. Lynne Parshall		For	For
	3	Spencer Berthelsen		For	For
	4	Joan Herman		For	For
2.	To approve an amendment and restatement of the Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under such plan by 800,000 shares to an aggregate of 2,800,000 shares, reduce the amount of the automatic awards under the plan, revise the vesting schedule of awards and extend the term of the plan.		Management	For	For
3.	To ratify amending the existing stock option and restricted stock unit awards of directors to adjust vesting.		Management	For	For
4.	To approve, by non-binding vote, executive compensation.		Management	For	For
5.	Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2020 fiscal year.		Management	For	For

IOVANCE BIOTHERAPEUTICS, INC.

Security	462260100	Meeting Type	Annual
Ticker Symbol	IOVA	Meeting Date	08-Jun-2020
Record Date	16-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Iain Dukes, D. Phil		For	For
	2	Maria Fardis, PhD, MBA		For	For
	3	Athena Countouriotis MD		For	For
	4	Ryan Maynard		For	For
	5	Merrill A. McPeak		For	For
	6	Wayne P. Rothbaum		For	For
	7	Michael Weiser, MD, PhD		For	For
2.	To approve, by non-binding advisory vote, the compensation of our named executive officers		Management	For	For
3.	To approve, by non-binding advisory vote, the frequency of future votes on the compensation of our named executive officers		Management	For	For
4.	To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder from 6,000,000 shares to 14,000,000 shares		Management	For	For
5.	To approve our 2020 Employee Stock Purchase Plan		Management	For	For
6.	To ratify the appointment of Marcum LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020		Management	For	For

JAZZ PHARMACEUTICALS PLC

Security	G50871105	Meeting Type	Annual
Ticker Symbol	JAZZ	Meeting Date	01-Aug-2019
Record Date	05-Jun-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Paul L. Berns	Management	For	For
1b.	Election of Director: Patrick G. Enright	Management	For	For
1c.	Election of Director: Seamus Mulligan	Management	For	For
1d.	Election of Director: Norbert G. Riedel	Management	For	For
2.	To ratify, on a non-binding advisory basis, the appointment of KPMG, Dublin as the independent auditors of Jazz Pharmaceuticals plc for the fiscal year ending December 31, 2019 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to determine the auditors' remuneration.	Management	For	For
3.	To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive officers as disclosed in the proxy statement.	Management	For	For

KODIAK SCIENCES INC.

Security	50015M109	Meeting Type	Annual
Ticker Symbol	KOD	Meeting Date	08-Jun-2020
Record Date	09-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Taiyin Yang, Ph.D.		For	For
	2	Bassil I. Dahiyat, PhD		For	For
	3	Charles Bancroft		For	For
2.	To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2020.		Management	For	For

LIGAND PHARMACEUTICALS INCORPORATED

Security	53220K504	Meeting Type	Annual
Ticker Symbol	LGND	Meeting Date	10-Jun-2020
Record Date	14-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Jason M. Aryeh		For	For
	2	Sarah Boyce		For	For
	3	Todd C. Davis		For	For
	4	Nancy R. Gray, Ph.D.		For	For
	5	John L. Higgins		For	For
	6	John W. Kozarich, Ph.D.		For	For
	7	John L. LaMattina, Ph.D		For	For
	8	Sunil Patel		For	For
	9	Stephen L. Sabba, M.D.		For	For
2.	Ratification of Ernst & Young LLP as Ligand's Independent Registered Public Accounting Firm.		Management	For	For
3.	Approval, on an advisory basis, of the Compensation of the Named Executive Officers.		Management	For	For

MADRIGAL PHARMACEUTICALS INC.

Security	558868105	Meeting Type	Annual
Ticker Symbol	MDGL	Meeting Date	17-Jun-2020
Record Date	24-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Paul A. Friedman, M.D.		For	For
	2	Kenneth M. Bate		For	For
	3	James M. Daly		For	For
2.	To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For
3.	Advisory vote on compensation of named executive officers.		Management	For	For
4.	In their discretion, the proxies are authorized to vote and act upon any other matters which may properly come before the meeting or any adjournment or postponement thereof.		Management	For	For

MAGENTA THERAPEUTICS INC

Security	55910K108	Meeting Type	Annual
Ticker Symbol	MGTA	Meeting Date	05-Jun-2020
Record Date	06-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Jeffrey Albers		For	For
	2	Michael W. Bonney		For	For
	3	Anne McGeorge		For	For
	4	David T. Scadden, M.D.		For	For
2.	To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For

MEDPACE HOLDINGS, INC.

Security	58506Q109	Meeting Type	Annual
Ticker Symbol	MEDP	Meeting Date	15-May-2020
Record Date	20-Mar-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Brian T. Carley		For	For
	2	Thomas C. King		For	For
	3	Robert O. Kraft		For	For
2.	To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending December 31, 2020.		Management	For	For
3.	To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement for the 2020 Annual Meeting.		Management	For	For
4.	To recommend, on an advisory basis, the frequency of the advisory vote on named executive officer compensation.		Management	1 Year	For

MILESTONE PHARMACEUTICALS INC.

Security	59935V107	Meeting Type	Annual
Ticker Symbol	MIST	Meeting Date	05-Jun-2020
Record Date	07-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1	DIRECTOR		Management
	1	Joseph Oliveto		For	For
	2	Paul Edick		For	For
	3	Richard Pasternak		For	For
	4	Debra K. Liebert		For	For
	5	Michael Tomsicek		For	For
	6	Paul Truex		For	For
2	Appointment of PricewaterhouseCoopers LLP as auditors for the Company to hold office until the close of the 2021 Annual Meeting of Shareholders and the Board of Directors of the Company is hereby authorized to fix the auditors' remuneration.		Management	For	For

MIRATI THERAPEUTICS, INC.

Security	60468T105	Meeting Type	Annual
Ticker Symbol	MRTX	Meeting Date	12-May-2020
Record Date	19-Mar-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Charles M. Baum		For	For
	2	Bruce L.A. Carter		For	For
	3	Julie M. Cherrington		For	For
	4	Aaron I. Davis		For	For
	5	Henry J. Fuchs		For	For
	6	Michael Grey		For	For
	7	Faheem Hasnain		For	For
	8	Craig Johnson		For	For
	9	Maya Martinez-Davis		For	For
2.	To approve, on an advisory basis, the compensation paid to our named executive officers as disclosed in the proxy statement.		Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020.		Management	For	For

MODERNA, INC.

Security	60770K107	Meeting Type	Annual
Ticker Symbol	MRNA	Meeting Date	29-Apr-2020
Record Date	02-Mar-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Stephen Berenson		For	For
	2	Sandra Horning, MD		For	For
	3	Paul Sagan		For	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2020.		Management	For	For
3.	To cast a non-binding, advisory vote to approve the compensation of our named executive officers.		Management	For	For
4.	To cast a non-binding, advisory vote on the frequency of future non-binding, advisory votes to approve the compensation of our named executive officers every.		Management	2 Years	Against

MOLECULAR TEMPLATES, INC.

Security	608550109	Meeting Type	Annual
Ticker Symbol	MTEM	Meeting Date	28-May-2020
Record Date	08-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Eric E. Poma, Ph.D.	Management	For	For
1.2	Election of Director: Harold E. Selick, Ph.D.	Management	For	For
2.	Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.	Management	For	For
3.	Approve on an advisory basis the compensation of the Company's named executive officers, as disclosed pursuant to the compensation disclosure rules of the Securities and Exchange Commission.	Management	For	For

MOMENTA PHARMACEUTICALS, INC.

Security	60877T100	Meeting Type	Annual
Ticker Symbol	MNTA	Meeting Date	23-Jun-2020
Record Date	27-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class I Director: Bruce L. Downey	Management	For	For
1B.	Election of Class I Director: Georges Gemayel	Management	For	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020	Management	For	For
3.	To approve, on an advisory (non-binding) basis, the compensation of our named executive officers	Management	For	For
4.	To approve the amendment and restatement of the Momenta Pharmaceuticals, Inc. 2013 Incentive Award Plan, which, among other things, increases the number of shares authorized for issuance by 7,000,000 shares.	Management	For	For

MYLAN N.V.

Security	N59465109	Meeting Type	Special
Ticker Symbol	MYL	Meeting Date	15-Jun-2020
Record Date	05-Feb-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of the Combination Proposal: (A) Approval of the Mylan Merger; (B) Approval of the Share Sale; (C) Approval of the Mylan Newco Liquidation; (D) Approval of the Alternative Transaction Structure; and (E) Approval of the Discharge of Directors (in each case with the foregoing capitalized terms as defined in the accompanying proxy statement).	Management	For	For
2.	Adoption of a non-binding, advisory resolution to adopt the compensation that will or may be paid or become payable to Mylan's named executive officers in connection with, or following, the consummation of the Combination as described in the proxy statement.	Management	For	For
3.	Adoption of a non-binding, advisory resolution to adopt certain features of Newco's governance which will replace the corresponding features of Mylan's governance, effective upon the closing of the Combination, relating to (i) the right of stockholders to nominate directors and make other stockholder proposals at stockholder meetings and (ii) director terms and stockholder removal of directors.	Management	For	For
4.	Adoption of a non-binding, advisory resolution to adopt certain features of Newco's governance which will replace the corresponding features of Mylan's governance, effective upon the closing of the Combination, relating to the right of stockholders to call special meetings of stockholders.	Management	For	For

MYLAN N.V.

Security	N59465109	Meeting Type	Special
Ticker Symbol	MYL	Meeting Date	30-Jun-2020
Record Date	02-Jun-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Appointment of the Director: Heather Bresch	Management	For	For
1B.	Appointment of the Director: Hon. Robert J. Cindrich	Management	For	For
1C.	Appointment of the Director: Robert J. Coury	Management	For	For
1D.	Appointment of the Director: JoEllen Lyons Dillon	Management	For	For
1E.	Appointment of the Director: Neil Dimick, C.P.A.	Management	For	For
1F.	Appointment of the Director: Melina Higgins	Management	For	For
1G.	Appointment of the Director: Harry A. Korman	Management	For	For
1H.	Appointment of the Director: Rajiv Malik	Management	For	For
1I.	Appointment of the Director: Richard Mark, C.P.A.	Management	For	For
1J.	Appointment of the Director: Mark W. Parrish	Management	For	For
1K.	Appointment of the Director: Pauline van der Meer Mohr	Management	For	For
1L.	Appointment of the Director: Randall L. (Pete) Vanderveen, Ph.D.	Management	For	For
1M.	Appointment of the Director: Sjoerd S. Vollebregt	Management	For	For
2.	Approval, on an advisory basis, of the compensation of the named executive officers of the Company.	Management	For	For
3.	Adoption of the Dutch annual accounts for fiscal year 2019.	Management	For	For
4.	Ratification of the selection of Deloitte & Touche LLP as Mylan's independent registered public accounting firm for fiscal year 2020.	Management	For	For
5.	Instruction to Deloitte Accountants B.V. for the audit of Mylan's Dutch statutory annual accounts for fiscal year 2020.	Management	For	For
6.	Authorization of the Board to acquire shares in the capital of the Company.	Management	For	For
7.	Delegation to the Board of the authority to issue ordinary shares and grant rights to subscribe for ordinary shares in the capital of the Company and to exclude or restrict pre-emptive rights.	Management	For	For
E1E	Approval of the Combination Proposal. ...(due to space limits, see proxy material for full proposal).	Management	For	For
E2E	Adoption of a non-binding, advisory resolution to adopt the compensation that will or may be paid or become payable to Mylan's named executive officers in connection with, or following, the consummation of the Combination as described in the proxy statement.	Management	For	For
E3E	Adoption of a non-binding, advisory resolution to adopt certain features of Newco's governance which will replace the corresponding features of Mylan's governance, effective upon the closing of the Combination, relating to (i) the right of stockholders to nominate directors and make other stockholder proposals at stockholder meetings and (ii) director terms and stockholder removal of directors.	Management	For	For
E4E	Adoption of a non-binding, advisory resolution to adopt certain features of Newco's governance which will replace the corresponding features of Mylan's governance, effective upon the closing of the Combination, relating to the right of stockholders to call special meetings of stockholders.	Management	For	For

MYOKARDIA, INC.

Security	62857M105	Meeting Type	Annual
Ticker Symbol	MYOK	Meeting Date	18-Jun-2020
Record Date	20-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	David P. Meeker, M.D.		For	For
	2	Mark L. Perry		For	For
	3	Wendy L. Yarno		For	For
2.	To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020.		Management	For	For
3.	To recommend, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement.		Management	For	For

MYRIAD GENETICS, INC.

Security	62855J104	Meeting Type	Annual
Ticker Symbol	MYGN	Meeting Date	05-Dec-2019
Record Date	08-Oct-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Mark C. Capone		For	For
	2	Heiner Dreismann Ph.D.		For	For
	3	Colleen F. Reitan		For	For
2.	To approve a proposed amendment to our 2017 Employee, Director and Consultant Equity Incentive Plan, as amended.		Management	For	For
3.	To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2020.		Management	For	For
4.	To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement.		Management	For	For

NEKTAR THERAPEUTICS

Security	640268108	Meeting Type	Annual
Ticker Symbol	NKTR	Meeting Date	17-Jun-2020
Record Date	20-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Karin Eastham	Management	For	For
1B.	Election of Director: Myriam J. Curet	Management	For	For
1C.	Election of Director: Howard W. Robin	Management	For	For
2.	To approve an amendment of our Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under the plan by 10,000,000 shares.	Management	For	For
3.	To approve an amendment and restatement of our Amended and Restated Employee Stock Purchase Plan to increase the aggregate number of shares of common stock authorized under the plan by 1,000,000 shares.	Management	For	For
4.	To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.	Management	For	For
5.	To approve a non-binding advisory resolution regarding our executive compensation (a "say-on-pay" vote).	Management	For	For

NEUROCRINE BIOSCIENCES, INC.

Security	64125C109	Meeting Type	Annual
Ticker Symbol	NBIX	Meeting Date	19-May-2020
Record Date	23-Mar-2020

Item	Proposal		Proposed  by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Kevin C. Gorman, Ph.D.		For	For
	2	Gary A. Lyons		For	For
2.	Advisory vote to approve the compensation paid to the Company's named executive officers.		Management	For	For
3.	To approve the Company's 2020 Equity Incentive Plan.		Management	For	For
4.	To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For

NOVAVAX, INC.

Security	670002401	Meeting Type	Annual
Ticker Symbol	NVAX	Meeting Date	25-Jun-2020
Record Date	29-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Stanley C. Erck		For	For
	2	Rajiv I. Modi, Ph.D.		For	For
2.	To approve, on an advisory basis, the compensation paid to our Named Executive Officers.		Management	For	For
3.	To amend and restate the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended to increase individual and non-employee director stock award limits granted to any person in any calendar year, and to increase the number of shares of the Company's common stock, par value $0.01, available for issuance thereunder by 7,100,000 shares.		Management	For	For
4.	To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For

NOVOCURE LIMITED

Security	G6674U108	Meeting Type	Annual
Ticker Symbol	NVCR	Meeting Date	10-Jun-2020
Record Date	03-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Jeryl Hilleman	Management	For	For
1B.	Election of Director: David Hung	Management	For	For
1C.	Election of Director: Kinyip Gabriel Leung	Management	For	For
1D.	Election of Director: Martin Madden	Management	For	For
1E.	Election of Director: Sherilyn McCoy	Management	For	For
2.	The approval and ratification of the appointment, by the Audit Committee of our Board of Directors, of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the auditor and independent registered public accounting firm of the Company for the Company's fiscal year ending December 31, 2020.	Management	For	For
3.	A non-binding advisory vote to approve executive compensation.	Management	For	For

OCULIS SA

Security	Meeting Type	Extraordinary General Meeting
Ticker Symbol	Meeting Date	26-Nov-2019
Record Date

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Ordinary Share Capital Increase	Management	For	For
2.	Conditional Share Capital Increase	Management	For	For

OCULIS SA

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	9-Mar-2020
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Ordinary Share Capital Increase	Management	For	For
2.	Conditional Share Capital Increase	Management	For	For

OCULIS SA

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	9-Mar-2020
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Ordinary Share Capital Increase	Management	For	For
2.	Conditional Share Capital Increase	Management	For	For

OCULIS SA

Security	N/A	Meeting Type	Annual General Meeting
Ticker Symbol	N/A	Meeting Date	25-Jun-2020
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of Annual Report including Financial Statements	Management	For	For
2.	Appropriation of Balance Sheet Result 2019	Management	For	For
3.	Discharge of the Members of the Board and Management	Management	For	For
4.	Re-Election of Board of Directors	Management	For	For
5.	Re-Election of the Auditors	Management	For	For

OVID THERAPEUTICS INC.

Security	690469101	Meeting Type	Annual
Ticker Symbol	OVID	Meeting Date	04-Jun-2020
Record Date	09-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class III director to hold office until the 2023 Annual Meeting of Stockholders: Jeremy M. Levin	Management	For	For
1B.	Election of Class III director to hold office until the 2023 Annual Meeting of Stockholders: Karen Bernstein	Management	For	For
2.	Ratification of the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.	Management	For	For

PIERIS PHARMACEUTICALS, INC.

Security	720795103	Meeting Type	Annual
Ticker Symbol	PIRS	Meeting Date	31-Jul-2019
Record Date	03-Jun-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	James Geraghty		For	For
	2	Ann Barbier, M.D.,Ph.D.		For	For
2.	Approve the Company's 2019 Employee, Director and Consultant Equity Incentive Plan.		Management	For	For
3.	Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For

PIERIS PHARMACEUTICALS, INC.

Security	720795103	Meeting Type	Annual
Ticker Symbol	PIRS	Meeting Date	23-Jun-2020
Record Date	24-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Stephen S. Yoder		For	For
	2	Michael Richman		For	For
	3	Matthew L. Sherman, M.D		For	For
2.	Approve the Company's 2020 Employee, Director and Consultant Equity Incentive Plan.		Management	For	For
3.	Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For
4	Approve, on non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement.		Management	For	For
5.	The preferred frequency for future non-binding advisory votes to approve the compensation of the Company's named executive officers.		Management	1 Year	For

PORTOLA PHARMACEUTICALS, INC.

Security	737010108	Meeting Type	Annual
Ticker Symbol	PTLA	Meeting Date	12-Jun-2020
Record Date	17-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Jeffrey Bird, M.D., PhD		For	For
	2	John H. Johnson		For	For
	3	H. Ward Wolff		For	For
2.	To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement.		Management	For	For
3.	To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For

PRA HEALTH SCIENCES, INC.

Security	69354M108	Meeting Type	Annual
Ticker Symbol	PRAH	Meeting Date	18-May-2020
Record Date	20-Mar-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Colin Shannon		For	For
	2	James C. Momtazee		For	For
	3	Alexander G. Dickinson		For	For
2.	To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for 2020.		Management	For	For
3.	Approval, in a non-binding advisory vote, of the compensation paid to the Company's named executive officers.		Management	For	For
4.	Approval of the PRA Health Sciences, Inc. 2020 Stock Incentive Plan.		Management	For	For

PTC THERAPEUTICS, INC.

Security	69366J200	Meeting Type	Annual
Ticker Symbol	PTCT	Meeting Date	10-Jun-2020
Record Date	17-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1	DIRECTOR		Management
	1	Stephanie S. Okey, M.S.		For	For
	2	Stuart W. Peltz, Ph.D.		For	For
	3	Jerome B. Zeldis, M.D.		For	For
2	Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For
3	Advisory vote to approve named executive officer compensation.		Management	For	For

PUMA BIOTECHNOLOGY, INC.

Security	74587V107	Meeting Type	Annual
Ticker Symbol	PBYI	Meeting Date	09-Jun-2020
Record Date	15-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Alan H. Auerbach		For	For
	2	Ann C. Miller		For	For
	3	Michael P. Miller		For	For
	4	Jay M. Moyes		For	For
	5	Hugh O'Dowd		For	For
	6	Adrian M. Senderowicz		For	For
	7	Troy E. Wilson		For	For
	8	Frank E. Zavrl		For	For
2.	Ratification of the selection of KPMG LLP as independent registered public accounting firm of Puma Biotechnology, Inc. for the fiscal year ending December 31, 2020.		Management	For	For
3.	Advisory (non-binding) vote to approve the compensation of Puma Biotechnology, Inc.'s named executive officers as described in the proxy statement.		Management	For	For

QUOTIENT LIMITED

Security	G73268107	Meeting Type	Annual
Ticker Symbol	QTNT	Meeting Date	30-Oct-2019
Record Date	28-Aug-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Franz Walt		For	For
	2	Thomas Bologna		For	For
	3	Frederick Hallsworth		For	For
	4	Brian McDonough		For	For
	5	Sarah O'Connor		For	For
	6	Heino von Prondzynski		For	For
	7	Zubeen Shroff		For	For
	8	John Wilkerson		For	For
9.	Proposal to re-appoint Ernst & Young LLP as our auditors to hold office from the conclusion of this meeting until the conclusion of the Annual Meeting of the Company to be held in 2020, that the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for purposes of United States securities law reporting for the fiscal year ending March 31, 2020 be ratified and that the directors be authorized.		Management	For	For

RAINIER THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	11-Jul-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Authorization and Approval of Unsecured Note Amendment and Secured Note Financing	Management	For	For
2.	Security Interest Grant to Note Recipients	Management	For	For
3.	General Authorizing Resolution	Management	For	For

RAINIER THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	30-Oct-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Adoption of Change in Control Retention Plan	Management	For	For
2.	General Authorizing Resolution	Management	For	For

RAINIER THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	3-Mar-2020
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Asset Purchase Agreement	Management	For	For
2.	Appointment of Seller's Representative	Management	For	For
3.	Waiver of Notice Requirement	Management	For	For
4.	Series A and Series B Stockholder Waiver	Management	For	For
5.	Interested Party Transactions	Management	For	For
6.	General Authorizing Resolution	Management	For	For

RAINIER THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	19-May-2020
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Adoption of Plan of Complete Liquidation, Liquidation and Dissolution	Management	For	For
2.	Interested Party Transactions	Management	For	For
3.	Waiver of Notice Requirement	Management	For	For
4.	General Authorizing Resolution	Management	For	For

RA PHARMACEUTICALS, INC.

Security	74933V108	Meeting Type	Special
Ticker Symbol	RARX	Meeting Date	17-Dec-2019
Record Date	12-Nov-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1.	The proposal to adopt the Merger Agreement.	Management	For	For
2.	The proposal to approve the adjournment of the Special Meeting to a later date or dates if necessary to solicit additional proxies if there are insufficient votes to approve the proposal to adopt the Merger Agreement at the time of the Special Meeting.	Management	For	For

RALLYBIO HOLDINGS, LLC

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	14-May-2020
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Series B Expansion	Management	For	For

REATA PHARMACEUTICALS, INC.

Security	75615P103	Meeting Type	Annual
Ticker Symbol	RETA	Meeting Date	10-Jun-2020
Record Date	16-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	James E. Bass		For	For
	2	R. Kent McGaughy, Jr.		For	For
2.	To approve, on an advisory basis, the compensation of our named executive officers.		Management	For	For
3.	To approve, on an advisory basis, the frequency of future advisory votes to approve the compensation of our named executive officers.		Management	1 Year	For
4.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For

REGENERON PHARMACEUTICALS, INC.

Security	75886F107	Meeting Type	Annual
Ticker Symbol	REGN	Meeting Date	12-Jun-2020
Record Date	14-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: N. Anthony Coles, M.D.	Management	For	For
1B.	Election of Director: Joseph L. Goldstein, M.D.	Management	For	For
1C.	Election of Director: Christine A. Poon	Management	For	For
1D.	Election of Director: P. Roy Vagelos, M.D.	Management	For	For
1E.	Election of Director: Huda Y. Zoghbi, M.D.	Management	For	For
2.	Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.	Management	For	For
3.	Proposal to approve the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan.	Management	For	For
4.	Proposal to approve, on an advisory basis, executive compensation.	Management	For	For

REVANCE THERAPEUTICS, INC.

Security	761330109	Meeting Type	Annual
Ticker Symbol	RVNC	Meeting Date	14-May-2020
Record Date	16-Mar-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Jill Beraud		For	For
	2	Robert Byrnes		For	For
2.	Ratification of the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For
3.	Approval of, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement.		Management	For	For

ROCKET PHARMACEUTICALS, INC.

Security	77313F106	Meeting Type	Annual
Ticker Symbol	RCKT	Meeting Date	16-Jun-2020
Record Date	20-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Roderick Wong	Management	For	For
1B.	Election of Director: Carsten Boess	Management	For	For
1C.	Election of Director: Pedro Granadillo	Management	For	For
1D.	Election of Director: Gotham Makker	Management	For	For
1E.	Election of Director: Gaurav Shah	Management	For	For
1F.	Election of Director: David P. Southwell	Management	For	For
1G.	Election of Director: Naveen Yalamanchi	Management	For	For
1H.	Election of Director: Elisabeth Björk	Management	For	For
2.	Ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.	Management	For	For
3.	Stockholder proposal to amend the Company's articles of incorporation and/or by-laws to provide that directors shall be elected by the affirmative vote of the majority of votes cast at an annual meeting of stockholders in uncontested elections.	Shareholder	Against	For

RUBIUS THERAPEUTICS, INC.

Security	78116T103	Meeting Type	Annual
Ticker Symbol	RUBY	Meeting Date	21-May-2020
Record Date	24-Mar-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Noubar B. Afeyan		For	For
	2	Michael Rosenblatt		For	For
	3	Catherine A. Sohn		For	For
2.	To ratify the appointment of PricewaterhouseCoopers LLP as Rubius Therapeutics, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For

SAGE THERAPEUTICS, INC.

Security	78667J108	Meeting Type	Annual
Ticker Symbol	SAGE	Meeting Date	09-Jun-2020
Record Date	13-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Michael F. Cola		For	For
	2	Jeffrey M. Jonas, M.D.		For	For
2.	To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For
3.	To hold a non-binding advisory vote to approve the compensation paid to our named executive officers.		Management	For	For

SANGAMO THERAPEUTICS, INC.

Security	800677106	Meeting Type	Annual
Ticker Symbol	SGMO	Meeting Date	18-May-2020
Record Date	20-Mar-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Robert F. Carey	Management	For	For
1.2	Election of Director: Stephen G. Dilly, M.B.B.S., Ph.D.	Management	For	For
1.3	Election of Director: Alexander D. Macrae, M.B., Ch.B., Ph.D.	Management	For	For
1.4	Election of Director: John H. Markels, Ph.D.	Management	For	For
1.5	Election of Director: James R. Meyers	Management	For	For
1.6	Election of Director: H. Stewart Parker	Management	For	For
1.7	Election of Director: Saira Ramasastry	Management	For	For
1.8	Election of Director: Karen L. Smith M.D., Ph.D., M.B.A., L.L.M.	Management	For	For
1.9	Election of Director: Joseph S. Zakrzewski	Management	For	For
2.	To approve, on an advisory basis, the compensation of our named executive officers, as described in the accompanying proxy statement	Management	For	For
3.	To approve the amendment and restatement of the Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan, or the 2018 Plan, to, among other things, increase the aggregate number of shares of our common stock reserved for issuance under the 2018 Plan by 9,900,000 shares	Management	For	For
4.	To approve an amendment to our Seventh Amended and Restated Certificate of Incorporation, as amended, to increase the total number of shares of our common stock authorized for issuance from 160,000,000 shares to 320,000,000 shares	Management	For	For
5.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2020	Management	For	For

SANOFI

Security	80105N105	Meeting Type	Annual
Ticker Symbol	SNY	Meeting Date	28-Apr-2020
Record Date	30-Mar-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of the individual company financial statements for the year ended December 31, 2019	Management	For	For
2.	Approval of the consolidated financial statements for the year ended December 31, 2019	Management	For	For
3.	Appropriation of results for the year ended December 31, 2019 and declaration of dividend	Management	For	For
4.	Approval of regulated agreements and commitments falling within the scope of Articles L. 225-38 et seq of the French Commercial Code	Management	For	For
5.	Ratification of the co-opting of Paul Hudson as a Director	Management	For	For
6.	Reappointment of Laurent Attal as a Director	Management	For	For
7.	Reappointment of Carole Piwnica as a Director	Management	For	For
8.	Reappointment of Diane Souza as a Director	Management	For	For
9.	Reappointment of Thomas Südhof as a Director	Management	For	For
10.	Appointment of Rachel Duan as a Director	Management	For	For
11.	Appointment of Lise Kingo as a Director	Management	For	For
12.	Determination of the compensation amount for the Board of Directors	Management	For	For
13.	Approval of the compensation policy for directors	Management	For	For
14.	Approval of the compensation policy for the Chairman of the Board of Directors	Management	For	For
15.	Approval of the compensation policy for the Chief Executive Officer	Management	For	For
16.	Approval of the report on the compensation of corporate officers issued in accordance with Article L. 225-37-3 I. of the French Commercial Code	Management	For	For
17.	Approval of the components of the compensation paid or awarded in respect of the year ended 31 December 2019 to Serge Weinberg, Chairman of the Board	Management	For	For
18.	Approval of the components of the compensation paid or awarded in respect of the year ended 31 December 2019 to Paul Hudson, Chief Executive Officer from September 1, 2019	Management	For	For
19.	Approval of the components of the compensation paid or awarded in respect of the year ended 31 December 2019 to Olivier Brandicourt, Chief Executive Officer until August 31, 2019	Management	For	For
20.	Authorization to the Board of Directors to carry out transactions in the Company's shares (usable outside the period of a public tender offer)	Management	For	For
21.	Powers for formalities	Management	For	For

SAREPTA THERAPEUTICS INC.

Security	803607100	Meeting Type	Annual
Ticker Symbol	SRPT	Meeting Date	04-Jun-2020
Record Date	13-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Douglas S. Ingram	Management	For	For
1.2	Election of Director: Hans Wigzell, M.D., Ph.D.	Management	For	For
1.3	Election of Director: Mary Ann Gray, Ph.D.	Management	For	For
2.	ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION	Management	For	For
3.	APPROVAL OF AN AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 99,000,000 TO 198,000,000 SHARES	Management	For	For
4.	APPROVAL OF AN AMENDMENT TO THE COMPANY'S 2018 EQUITY INCENTIVE PLAN TO INCREASE THE MAXIMUM AGGREGATE NUMBER OF SHARES OF COMMON STOCK THAT MAY BE ISSUED PURSUANT TO AWARDS GRANTED UNDER THE 2018 EQUITY INCENTIVE PLAN BY 3,800,000 SHARES TO 8,187,596 SHARES	Management	For	For
5.	RATIFICATION OF KPMG LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2020	Management	For	For

SEATTLE GENETICS, INC.

Security	812578102	Meeting Type	Annual
Ticker Symbol	SGEN	Meeting Date	15-May-2020
Record Date	19-Mar-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class I Director: David W. Gryska	Management	For	For
1.2	Election of Class I Director: John A. Orwin	Management	For	For
1.3	Election of Class I Director: Alpna H. Seth	Management	For	For
2.	Approve, on an advisory basis, the compensation of Seattle Genetics' named executive officers as disclosed in the accompanying proxy statement.	Management	For	For
3.	Approve the amendment and restatement of the Seattle Genetics, Inc. Amended and Restated 2007 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance thereunder by 6,000,000 shares.	Management	For	For
4.	Ratify the appointment of PricewaterhouseCoopers LLP as Seattle Genetics' independent registered public accounting firm for the fiscal year ending December 31, 2020.	Management	For	For

SPECTRUM PHARMACEUTICALS, INC.

Security	84763A108	Meeting Type	Annual
Ticker Symbol	SPPI	Meeting Date	18-Jun-2020
Record Date	21-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: William L. Ashton	Management	For	For
1.2	Election of Director: Elizabeth A. Czerepak	Management	For	For
1.3	Election of Director: Seth H.Z. Fischer	Management	For	For
1.4	Election of Director: Joseph W. Turgeon	Management	For	For
1.5	Election of Director: Jeffrey L. Vacirca	Management	For	For
1.6	Election of Director: Dolatrai M. Vyas	Management	For	For
1.7	Election of Director: Bernice R. Welles	Management	For	For
2.	To approve, on a non-binding advisory basis, the compensation of our named executive officers, as disclosed in the Compensation Discussion and Analysis section of the Proxy Statement.	Management	For	For
3.	To approve the Amendment to the Spectrum Pharmaceuticals, Inc. 2018 Long-Term Incentive Plan.	Management	For	For
4.	To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.	Management	For	For

SUTRO BIOPHARMA, INC.

Security	869367102	Meeting Type	Annual
Ticker Symbol	STRO	Meeting Date	05-Jun-2020
Record Date	13-Apr-2020

Item	Proposal		Proposed  by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	William J. Newell		For	For
	2	Connie Matsui		For	For
	3	James Panek		For	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For

SYNEOS HEALTH, INC.

Security	87166B102	Meeting Type	Annual
Ticker Symbol	SYNH	Meeting Date	27-May-2020
Record Date	30-Mar-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Bernadette M. Connaughton	Management	For	For
1B.	Election of Director: Kenneth F. Meyers	Management	For	For
1C.	Election of Director: Matthew E. Monaghan	Management	For	For
1D.	Election of Director: Joshua M. Nelson	Management	For	For
2.	To approve on an advisory (nonbinding) basis our executive compensation.	Management	For	For
3.	To ratify the appointment of the Company's independent auditors Deloitte & Touche LLP.	Management	For	For

TETRAPHASE PHARMACEUTICALS, INC.

Security	88165N105	Meeting Type	Special
Ticker Symbol	TTPH	Meeting Date	25-Sep-2019
Record Date	01-Aug-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To approve an amendment to our certificate of incorporation to effect a reverse stock split at a ratio of not less than 1-for-5 and not greater than 1-for-20, with the exact ratio to be set within that range at the discretion of our board of directors prior to our 2020 annual meeting of stockholders without further approval or authorization of our stockholders and with our board of directors able to elect to abandon such proposed amendment and not effect the reverse stock split authorized by stockholders, in its sole discretion.	Management	For	For

TETRAPHASE PHARMACEUTICALS, INC.

Security	88165N204	Meeting Type	Special
Ticker Symbol	TTPH	Meeting Date	08-Jun-2020
Record Date	22-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To adopt the Agreement and Plan of Merger, dated as of March 15, 2020 (as it may be amended from time to time), by and among AcelRx Pharmaceuticals, Inc., ("AcelRx"), Tetraphase Pharmaceuticals, Inc., a Delaware corporation ("Tetraphase"), and Consolidation Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of AcelRx ("Merger Sub"), pursuant to which Merger Sub will merge with and into Tetraphase, with Tetraphase as the surviving corporation and an indirect wholly owned subsidiary of AcelRx (the "Merger").	Management	For	For
2.	To approve, on a nonbinding advisory basis, "golden parachute" compensation payments that may be payable to Tetraphase's named executive officers in connection with the Merger.	Management	For	For
3.	To approve the adjournment of the Special Meeting of Tetraphase Pharmaceuticals, Inc. (the "Special Meeting") to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to approve Proposal 1 or to ensure that any supplement or amendment to the proxy statement/prospectus is timely provided to Tetraphase stockholders.	Management	For	For

THERAVANCE BIOPHARMA, INC.

Security	G8807B106	Meeting Type	Annual
Ticker Symbol	TBPH	Meeting Date	28-Apr-2020
Record Date	02-Mar-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Dean J. Mitchell	Management	For	For
1.2	Election of Director: George M. Whitesides	Management	For	For
1.3	Election of Director: William D. Young	Management	For	For
2.	Ratify the appointment of Ernst & Young LLP as Theravance Biopharma, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2020.	Management	For	For
3.	Approve a non-binding advisory resolution regarding executive compensation.	Management	For	For

TRILLIUM THERAPEUTICS INC.

Security	89620X506	Meeting Type	Annual and Special Meeting
Ticker Symbol	TRIL	Meeting Date	30-Jun-2020
Record Date	15-May-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1	DIRECTOR		Management
	1	Mr. Luke Beshar		For	For
	2	Dr. Robert Kirkman		For	For
	3	Mr. Paul Walker		For	For
	4	Dr. Thomas Reynolds		For	For
	5	Dr. Jan Skvarka		For	For
	6	Dr. Helen Tayton-Martin		For	For
2	To reappoint Ernst & Young, LLP, Chartered Professional Accountants, Licensed Public Accountants, as auditors of the Corporation for the ensuing year and to authorize the directors to fix the remuneration to be paid to the auditors.		Management	For	For
3	To consider, and if deemed appropriate, to pass an ordinary resolution of disinterested shareholders, the full text of which is set forth in the Circular, to approve the Corporation's omnibus equity incentive plan.		Management	For	For

TURNING POINT THERAPEUTICS, INC.

Security	90041T108	Meeting Type	Annual
Ticker Symbol	TPTX	Meeting Date	15-Jun-2020
Record Date	20-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Athena Countouriotis MD		For	For
	2	Patrick Machado, J.D.		For	For
	3	Garry Nicholson		For	For
2.	Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020.		Management	For	For

ULTRAGENYX PHARMACEUTICAL INC.

Security	90400D108	Meeting Type	Annual
Ticker Symbol	RARE	Meeting Date	26-Jun-2020
Record Date	27-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Emil D. Kakkis, M.D., Ph.D.	Management	For	For
1B.	Election of Director: Shehnaaz Suliman, M.D.	Management	For	For
1C.	Election of Director: Daniel G. Welch	Management	For	For
2.	Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.	Management	For	For
3.	Advisory (non-binding) vote to approve the compensation of our named executive officers.	Management	For	For

UNIQURE N.V.

Security	N90064101	Meeting Type	Annual
Ticker Symbol	QURE	Meeting Date	17-Jun-2020
Record Date	20-May-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Resolution to adopt the 2019 annual accounts and treatment of the results.	Management	For	For
2.	Resolution to discharge liability of the members of the Board for their management.	Management	For	For
3.	Reappointment of Madhavan Balachandran as non- executive director.	Management	For	For
4.	Reappointment of Jack Kaye as non-executive director.	Management	For	For
5.	Reappointment of Jeremy Springhorn as non-executive director.	Management	For	For
6.	Appointment of Leonard Post as non-executive director.	Management	For	For
7.	Resolution to reauthorize the Board to issue ordinary shares and options.	Management	For	For
8.	Resolution to reauthorize the Board to exclude or limit preemptive rights upon the issuance of ordinary shares.	Management	For	For
9.	Authorization of the Board to repurchase ordinary shares.	Management	For	For
10.	Resolution to appoint KPMG as external auditor of the Company for the 2020 financial year.	Management	For	For
11.	Advisory approval of compensation of named executive officers.	Management	For	For

UNITED THERAPEUTICS CORPORATION

Security	91307C102	Meeting Type	Annual
Ticker Symbol	UTHR	Meeting Date	26-Jun-2020
Record Date	30-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Raymond Dwek	Management	For	For
1B.	Election of Director: Christopher Patusky	Management	For	For
1C.	Election of Director: Tommy Thompson	Management	For	For
2.	Approval of an amendment to our Amended and Restated Certificate of Incorporation to declassify our Board of Directors and provide for the annual election of our directors	Management	For	For
3.	Advisory resolution to approve executive compensation	Management	For	For
4.	Approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan	Management	For	For
5.	Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2020	Management	For	For

VECTIVEBIO HOLDING AG

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	19-Dec-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of Bridge Loan	Management	For	For
2.	Amendment to Glypharma purchase agreement	Management	For	For

VECTIVEBIO HOLDING AG

Security	N/A	Meeting Type	Extraordinary General Meeting
Ticker Symbol	N/A	Meeting Date	6-Jan-2020
Record Date	N/A

Item	Proposal	Proposed  by	Vote	For/Against Management
1.	Election of Naveed Siddiqi as a new member of the board of directors of the company	Management	For	For

VECTIVEBIO HOLDING AG

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	24-Jun-2020
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Constitution of the meting and appointment of chair	Management	For	For
2.	Approval of the financial statements of the Company for the financial year ended December 31, 2019	Management	For	For
3.	Approval of the appropriation of the financial result 2019	Management	For	For
4	Approval of granting discharge to the members of the board of directors and officers from liability	Management
5	Re-election of the board of directors	Management	For	For
6	Re-election of the auditors	Management	For	For
4.	To approve the Arena Pharmaceuticals, Inc. 2020 Long- Term Incentive Plan.	Management	For	For
5.	To ratify the appointment of KPMG LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2020.	Management	For	For

VERONA PHARMA PLC

Security	925050106	Meeting Type	Annual
Ticker Symbol	VRNA	Meeting Date	16-Apr-2020
Record Date	13-Mar-2020

Item	Proposal	Proposed by	Vote	For/Against Management
O1	To receive and adopt the report of the directors and the financial statements for the year ended 31 December 2019.	Management	For	For
O2	To approve the Directors' Remuneration Report.	Management	For	For
O3	To re-elect Mr Rishi Gupta as a director of the Company.	Management	For	For
O4	To re-elect Dr Mahendra Shah as a director of the Company.	Management	For	For
O5	To re-elect Mr Vikas Sinha as a director of the Company.	Management	For	For
O6	To re-elect Dr David Zaccardelli as a director of the Company.	Management	For	For
O7	To appoint PricewaterhouseCoopers LLP as auditors.	Management	For	For
O8	To authorise the directors to determine the auditors' remuneration.	Management	For	For
O9	To approve amendments to the Verona Pharma plc 2017 Incentive Award Plan - Increase overall share limits.	Management	For	For
O10	To approve amendments to the Verona Pharma plc 2017 Incentive Award Plan - Extend the term of the Plan until 29th April 2030.	Management	For	For
O11	To authorise the directors to allot relevant securities pursuant to Section 551 of the Companies Act 2006.	Management	For	For
S12	To authorise the directors to allot equity securities pursuant to Section 570 of the Companies Act 2006.	Management	For	For

VERTEX PHARMACEUTICALS INCORPORATED

Security	92532F100	Meeting Type	Annual
Ticker Symbol	VRTX	Meeting Date	03-Jun-2020
Record Date	09-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Sangeeta Bhatia	Management	For	For
1B.	Election of Director: Lloyd Carney	Management	For	For
1C.	Election of Director: Alan Garber	Management	For	For
1D.	Election of Director: Terrence Kearney	Management	For	For
1E.	Election of Director: Reshma Kewalramani	Management	For	For
1F.	Election of Director: Yuchun Lee	Management	For	For
1G.	Election of Director: Jeffrey Leiden	Management	For	For
1H.	Election of Director: Margaret McGlynn	Management	For	For
1I.	Election of Director: Diana McKenzie	Management	For	For
1J.	Election of Director: Bruce Sachs	Management	For	For
2.	Ratification of Ernst & Young LLP as our independent Registered Public Accounting firm for the year ending December 31, 2020.	Management	For	For
3.	Advisory vote on named executive officer compensation.	Management	For	For
4.	Shareholder proposal, if properly presented at the meeting, requesting that we prepare a report on our policies and activities with respect to lobbying.	Shareholder	Against	For

VIELA BIO, INC.

Security	926613100	Meeting Type	Annual
Ticker Symbol	VIE	Meeting Date	18-Jun-2020
Record Date	20-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Andreas Wicki, Ph.D.		For	For
	2	Rachelle Jacques		For	For
2.	To ratify the appointment of KPMG LLP as Viela Bio, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2020.		Management	For	For

WAVE LIFE SCIENCES LTD.

Security	Y95308105	Meeting Type	Annual
Ticker Symbol	WVE	Meeting Date	08-Aug-2019
Record Date	17-Jun-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Paul B. Bolno, M.D., MBA	Management	For	For
1b.	Election of Director: Christian Henry	Management	For	For
1c.	Election of Director: Peter Kolchinsky, Ph.D.	Management	For	For
1d.	Election of Director: Koji Miura	Management	For	For
1e.	Election of Director: Adrian Rawcliffe	Management	For	For
1f.	Election of Director: Ken Takanashi	Management	For	For
1g.	Election of Director: Gregory L. Verdine, Ph.D.	Management	For	For
2.	To approve the re-appointment of KPMG LLP to serve as our independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2019, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP's remuneration for services provided through the date of our 2020 Annual General Meeting of Shareholders	Management	For	For
3.	To approve the Company's payment of cash and equity- based compensation to non-employee directors for service on the Board of Directors and its committees, in the manner and on the basis set forth under "Proposal 3: Non-Employee Directors' Compensation"	Management	For	For
4.	To authorize the Board of Directors to allot and issue Ordinary Shares of Wave Life Sciences Ltd.	Management	For	For
5.	To approve the Company's 2019 Employee Share Purchase Plan	Management	For	For
6.	To approve by a non-binding advisory vote the compensation of our named executive officers as disclosed in the proxy statement	Management	For	For
7.	To approve by a non-binding advisory vote the frequency of holding future advisory votes on the compensation of our named executive officers	Management	1 Year	For

XENCOR, INC.

Security	98401F105	Meeting Type	Annual
Ticker Symbol	XNCR	Meeting Date	25-Jun-2020
Record Date	27-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Bassil I. Dahiyat		For	For
	2	Ellen G. Feigal		For	For
	3	Kevin C. Gorman		For	For
	4	Kurt A. Gustafson		For	For
	5	Yujiro S. Hata		For	For
	6	A. Bruce Montgomery		For	For
	7	Richard J. Ranieri		For	For
	8	Dagmar Rosa-Bjorkeson		For	For
2.	Proposal to ratify RSM US LLP as the independent registered public accounting firm for 2020		Management	For	For
3.	Proposal to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy materials		Management	For	For

Y-MABS THERAPEUTICS, INC.

Security	984241109	Meeting Type	Annual
Ticker Symbol	YMAB	Meeting Date	11-Jun-2020
Record Date	17-Apr-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	James I. Healy, M.D.		For	For
	2	Ashutosh Tyagi, M.D.		For	For
	3	Laura J. Hamill		For	For
2.	Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020		Management	For	For

ZOGENIX, INC.

Security	98978L204	Meeting Type	Annual
Ticker Symbol	ZGNX	Meeting Date	29-May-2020
Record Date	09-Apr-2020

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Louis C. Bock	Management	For	For
1B.	Election of Director: Cam L. Garner	Management	For	For
1C.	Election of Director: Mark Wiggins	Management	For	For
2.	Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2020.	Management	For	For
3.	Approval, on an advisory basis, of the compensation of the named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission.	Management	For	For
4.	To approve an amendment and restatement of the Zogenix, Inc. 2010 Employee Stock Purchase Plan.	Management	For	For

ZYMEWORKS INC.

Security	98985W102	Meeting Type	Annual
Ticker Symbol	ZYME	Meeting Date	07-May-2020
Record Date	13-Mar-2020

Item	Proposal		Proposed by	Vote	For/Against Management
1	DIRECTOR		Management
	1	Hollings C. Renton		For	For
	2	Lota Zoth		For	For
2	To approve, on an advisory and non-binding basis, the compensation of the Company's named executive officers, as more particularly described in the accompanying proxy statement.		Management	For	For
3	To vote, on an advisory and non-binding basis, on the frequency of holding the advisory vote on the compensation of the Company's named executive officers in the future, as more particularly described in the accompanying proxy statement.		Management	1 Year	For
4	Appointment of KPMG LLP as Auditors of the Corporation for the ensuing year and authorizing the Directors to fix their remuneration.		Management	For	For

SIGNATURES

Pursuant to the requirements of the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

(Registrant)		Tekla Life Sciences Investors
By (Signature and Title)*
			/s/ Daniel R. Omstead
			(Daniel R. Omstead, President)
Date	8/17/20

*Print the name and title of each signing officer under his or her signature.